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In yeast, Cu,Zn-superoxide dismutase (Sod1) is activated by the copper metallochaperone 
Ccs1, mainly in the cytosol.  This involves the delivery of Cu1+ and the formation of a 
structurally important disulfide bond.  Ccs1 consists of three domains, with domain 1 (D1) 
and domain 3 (D3) containing copper-binding CXXC and CXC motifs respectively.  In human 
CCS1, D1 is the site of copper transfer and D3 is responsible for disulfide bond formation in 
SOD1.  In yeast cells, D3 of Ccs1 is essential for Sod1 activation, whereas D1 is required only 
under copper-limiting conditions.  The Cu1+-binding ability of Ccs1 has been investigated 
using mutants in which the Cys residues in either the D1 (C17S/C20S-Ccs1) or D3 
(C229S/C231S-Ccs1) copper-binding motif have been mutated to Ser residues, as well as a 
mutant lacking D3 (D1/2-Ccs1).  Both D1 and D3 of Ccs1 are able to bind a single equivalent 
of Cu1+, and dimerisation occurs upon Cu1+-binding both via a copper mediated process as 
well as by disulfide bond formation.  The Cu1+ affinity of D1 is (2.6 ± 0.5) x 1018 M-1 at pH 7.5, 
while that of D3 is six times weaker.  D1 of human CCS1 has a Cu1+ affinity which is over an 
order of magnitude greater than that of D3.  Aerobic incubation of reduced E,Zn-Sod1 with 
all Cu1+-loaded Ccs1 proteins produces catalytically active Cu,Zn-Sod1 containing the 
catalytically active disulfide bond.  Activation with C17S/C20S-Ccs1 is slightly lower than with 
the wild type protein, however removal of the copper-binding site in D3 (C229S/C231S-Ccs1 
and D1/2-Ccs1) has a much more marked effect.  A second cytosolic metallochaperone, Atx1, 
delivers Cu1+ to the copper-transporting P-type ATPase Ccc2 for incorporation into the 
membrane protein Fet3p.  The Cu1+ affinity of Atx1 is greater than those of the copper-
binding motifs of Ccs1.  Exchange of Cu1+ between D1 and D3 of Ccs1 and Atx1 occurs as 
expected on the basis of their Cu1+ affinities.  Ccs1 and Atx1 may collect Cu1+ from the same 










Units and Abbreviations 
 
Measurements and Techniques: 
M mol dm-3 Da Daltons 
L litre ε Extinction coefficient (M-1 cm-1) 
g gram nm nanometre 
µ micro   
m milli   
oC degrees celsius   
ppm parts per million   
 
MALDI matrix assisted laser desorption/ionization 
MS mass spectrometry 
CD circular dichroism 
PCR polymerase chain reaction 
AAS atomic force microscopy 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 




BCA bicinchoninic acid 
BCS bathocuproine disulfonic acid 
DTNB 5,5'-dithiobis-(2-nitrobenzoic acid) (Ellman’s reagent) 
EDTA ethylenediaminetetraacetic acid 
Tris tris(hydroxymethyl)aminoethane 
Hepes 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 







Ccs1 Copper metallochaperone for Cu,Zn-superoxide dismutase  
WT-Ccs1 Wild-type Ccs1 from S. cerevisiae 
C17S/C20S-Ccs1 Cys-to-Ser Ccs1 mutant 
C229S/C231S-Ccs1 Cys-to-Ser Ccs1 mutant 
D1/2-Ccs1 Ccs1 amino acid residues 1 - 249 
D2/3-Ccs1 Ccs1 amino acid residues 72 - 249 
CCS Ccs1 from H. sapiens 
Atx1 Copper metallochaperone from S. cerevisiae 
HAH1 Atx1 copper metallochaperone from H. sapiens 
Sod1 Cu,Zn-superoxide dismutase from S. cerevisiae 
SOD1 Sod1 from H. sapiens 
 
Amino acids: 
Alanine Ala A  Methionine Met M 
Cysteine Cys C  Asparagine Asn N 
Aspartic acid Asp D  Proline Pro P 
Glutamic acid Glu E  Glutamine Gln Q 
Phenylalanine Phe F  Arginine Arg R 
Glycine Gly G  Serine Ser S 
Histidine His H  Threonine Thr T 
Isoleucine Ile I  Valine Val V 
Lysine Lys K  Tyrptophan Trp W 
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1.1 The Chemistry of Copper 
Copper is a member of the first row d-block metals with the electronic configuration [Ar] 
3d10 4s1 and shares many of the characteristics particular to this group of elements.  Copper 
metal is a good conductor of electricity and many copper compounds are coloured due to 
electronic transitions.  Additionally, copper exhibits the prototypical transition metal ability 
to form compounds in many oxidation states due to a loss of d-electrons.  
 
1.1.1 Oxidation States 
Copper is the only first-row d-block metal to exhibit a stable +1 oxidation state, however in 
aqueous solution Cu1+ is disproportionated (simultaneously oxidised and reduced) to the 
solid metal and Cu2+ (Reaction 1.3).   
𝐶𝑢1+  →  𝐶𝑢2+ + 𝑒− 
 
Eo = - 0.153 V Reaction 1.1 
𝐶𝑢1+ +  𝑒−  → 𝐶𝑢(𝑠) 
 
Eo = + 0.521 V Reaction 1.2 
 
2𝐶𝑢1+  →  𝐶𝑢(𝑠) +  𝐶𝑢
2+ Eorcn = + 0.368 V Reaction 1.3 
 
The disproportionation of Cu1+ can be explained by the standard reduction potentials (Eo) of 
the half reactions that constitute the net Reaction 1.3.  Reaction 1.1 shows the oxidation of 
Cu1+ and Reaction 1.2 shows the reduction of Cu1+.  The combination of the Eo for the two 
half reaction provides a positive Eorcn for the net reaction.  The Nernst equation relates the Eo 
to the free Gibbs energy in an inverse relationship, therefore the Gibbs energy is negative 
(Equation 1.1), indicating a spontaneous disproportionation.   
 
∆𝐺 =  −𝑛𝐹𝐸 
ΔG = Gibbs free energy 
n = the number of electrons transferred in 
the half-reaction 
F = Faraday constant 








Also, the completely filled 3d subshell of Cu1+ ([Ar] 3d10) would be expected to be 
energetically favoured over the incomplete subshell of Cu2+ ([Ar] 3d9), yet Cu1+ is larger and 
has a lower charge density than Cu2+ resulting in a much lower enthalpy of hydration for 
Cu1+.   Nevertheless, it is possible to stabilise Cu1+ ions in solution with appropriate ligands 
such as the cyanide ion (CN-) as in Method 2.17.   
Compared to the other first row d-block metals, the divalent copper ion has a high reduction 
potential of +0.157 EO (V) for Cu2+/Cu1+, indicating that the release of an electron occurs less 
readily than hydrogen and Cu2+ is easily reduced to Cu1+.  This characteristic is exploited by 
biological systems through the interconversion of Cu2+ and Cu1+, allowing enzymes to utilize 
copper as a cofactor for electron transfer catalysis by cycling between the two oxidation 
states. 
A variety of Cu2+ compounds are coloured due to the incompletely filled 3d sub-shell which 
allows the promotion of an electron to a higher orbital upon interaction with a ligand.  It is 
therefore consistent that Cu1+ cannot absorb energy for d-d transitions as there are no 
empty/partially-empty orbitals available to accept a promoted electron.  This renders Cu1+ 
compounds colourless, except for when the counter ion is coloured or when charge transfer 
absorptions occur in the visible region.  
 
1.1.2 Ligand Preference 
The oxidation states of copper are also expected to have a preference for different ligands 
due to their allocation within the hard-soft acid base principle. Cu1+ is described as being a 
‘soft’ Lewis acid on account of the low positive charge, electron pairs in the valence shell and 
a larger ionic radius than the divalent ion. It is therefore expected for Cu1+ to prefer ‘soft’ 
bases such as sulphur-containing amino acids as ligands such as cysteine and methionine, 
and the bonding of these complexes is considered to be highly covalent in character. 
Contrary to this, Cu2+ is described as being a ‘hard’ or borderline Lewis acid due to the higher 
positive charge and increased ionic radius. This ion is predicted to prefer ‘hard’ bases as 
ligands such as those containing nitrogen or oxygen donor atoms, including the amino acid 
histidine and those containing carboxylates, such as aspartate and glutamate acid. 
Consequently, the bonding of Cu2+ complexes is anticipated to be dominated by charge 
interactions and possess more ionic characteristics.  
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1.1.3 Coordination Geometry 
Coordination geometries formed by Cu1+ are typical of ions with d10 configurations such as 
octahedral and tetrahedral.  Octahedral complexes of d9 ions, such as Cu2+, results in a 
degenerate electronic state and the system undergoes Jahn-Teller distortions whereby the 
axial bonds are elongated.  This has the effect of removing the degeneracy and lowering the 
overall energy, consequently Cu2+ complexes prefer distorted octahedral and square planar 
geometries. 
 
1.1.4 Protein Modulation of Metal Ion  
Isolated metal ions have particular properties, however incorporation into a metallo-protein 
often induces a modulation of these properties to increase the efficiency of a particular 
reaction.  This can involve solvation patterns or the creation of specific electrostatic fields to 
enhance reactivity of the active site.  Also, distinct coordination geometries enforced by the 
ligand sphere as described by the entatic state1 and the induced rack hypotheses2 have been 
suggested to explain the wide-ranging geometric and electronic characteristics of metal ions 
that are apparently adapted for function. 
 
1.2 Cellular Toxicity of Copper 
Copper is an essential micronutrient required for plant and animal health, however it is also 
associated with toxic effects. This toxicity has provided beneficial applications of copper, 
such as the creation of Bordeaux mixture to protect grapes from fungal infection,3 to 
disinfect hospital drinking-water against Legionella,4 and in 2008 became the first solid 
surface registered by the Environmental Protection Agency as an antimicrobial.  Also, copper 
has also been linked to host defence mechanisms such as the antimicrobial function of 
macrophages within the immune system5-10 and counteractive copper resistance 
mechanisms of pathogens.5, 11 One explanation of copper toxicity arises from the ability of 
the ion to cycle between a +1 and +2 oxidation state, catalysing the formation of the highly 
reactive hydroxyl radical via Haber-Weiss (Reaction 1.4)12 and Fenton-type reactions 






− + 𝐻2𝑂2  →  𝑂2 +  𝑂𝐻
− + 𝑂𝐻∙  Reaction 1.4 
𝐶𝑢+ +  𝐻2𝑂2  →  𝐶𝑢
2+ + 𝑂𝐻− +  𝑂𝐻∙  Reaction 1.5 
 
These radicals disrupt and damage cellular machinery through the oxidation of proteins, 
DNA and lipids, thereby inhibiting or altering normal cell function.  Toxicity is also attributed 
to copper’s ability to compete with other metal ions such as zinc, manganese and iron for 
protein binding sites.  This is explained by the position of Cu2+ in the Irving-Williams series 
which describes copper as forming complexes with a higher relative stability than other 
divalent ions of the first-row d-block metals.14  One example of damaging metal competition 
is inactivation of the dehydratase enzymes in Escherichia coli by copper due to disruption of 
the formation of iron-sulphur clusters via coordination of copper to the sulphur atoms and 
the displacement of iron.15  It has been shown that this is avoided in cyanobacteria through 
compartmentalization of the location and metal ion environment where specific protein-
folding takes place in the cell.16  The toxicity of copper demonstrates the high level of 
importance in strictly controlling the transportation and use of this metal within cells.  This is 
achieved through the use of metal chaperones which traffic copper to specific destinations.  
The chaperones also protect the metal ions from a highly chelating intracellular environment 
which in yeast was found to restrict the concentration of available copper to < 10-18 M.17  
 
1.3 The Role of Cysteine Residues in Proteins 
There are 20 naturally occurring amino acids which are the building blocks of proteins. They 
are linked by peptide bonds to form polypeptide chains and the side chain of each amino 
acid has different properties. These properties play an important role in influencing 
structure and allowing proteins to exhibit specific characteristics such as recognition by 
other biomolecules and the functioning of the active sites of enzymes. 
The side chain of cysteine is a thiol group (Figure 1.1) whose sulphur atom is electron-rich, 
polarizable and quite nucleophilic (a tendency to donate electrons or to react at electron-
poor sites). The nucleophilicity of cysteine is enhanced when it is in the deprotonated 
thiolate form.  
Cysteine is present in many proteins and has been found to perform a range of biological 
functions. These include contributing to the folding and stability of proteins via the form of 
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disulphide bonds, participating in enzymatic active sites, undergoing post-translational 
modifications and of key importance for this thesis, the binding of metal ions.  
 
 
Figure 1.1. The structures of cysteine and cystine. The structure of the amino acid cysteine, 
and of cysteine in which the two thiol groups of cysteine residues have formed a disulphide 
bond. The structures were made in ChemBioDraw Ultra. 
 
1.3.1 Cysteines and Protein Structure 
A protein’s structure is critically important for its function. Mis-folding can result in 
abhorrent behaviour or a detrimental lack of function (see section 1.8.3). Cysteine residues 
play an important role in increasing the rigidity and stabilising the structure of many proteins 
through the formation of covalent disulfide bonds (Reaction 1.6).  
2(RSH) → R-S-S-R +2e- +2H+ Reaction 1.6 
 
Disulfide bond formation results from the oxidation of cysteine residues.  The cellular cytosol 
has long been regarded as a reducing environment due to the presence of glutathione (GSH) 
which is a low-molecular weight molecule with a thiol group.18  Therefore, the reducing 
environment within the cytosol makes disulphide bond formation in proteins unlikely and 
production is usually localised to a specific cellular compartment. In eukaryotes this is mainly 
in the lumen of the endoplasmic reticulum whereas in Gram-negative bacteria it usually 
occurs in the periplasmic space.19 In Gram-positive bacteria, which have an absence of 
traditional periplasmic compartments, the pathways of protein oxidation have not been fully 
explored however the identification of proteins similar to thiol-disulfide oxidoreductases has 
been reported.20  Well documented examples of proteins that rely on disulphide bonds to 










Figure 1.2. Copper homeostasis in Sacharomyces cerevisiae. The high affinity transporter 
proteins Ctr1 and Ctr3,  surface metalloreductases Fre1 and Fre2, and low affinity 
transporter protein Fet4p are located at the cellular membrane. The high affinity transporter 
protein Ctr2 and metalloreductase Fre6 are located at the vacuole membrane. Cytochrome c 
oxidase (Cox) and copper chaperones for Cox (Cox17/Sco1/Sco2) are located in the 
mitochondria. The P-type ATPase Ccc2 is located at the Golgi body. The transcription factors 
Mac1 and Ace1 are located in the nucleus. The metallothioneins Cup1 and Crs5, Cu,Zn-
superoxide dismutase (Sod1), copper chaperone for Sod1 (Ccs1) and copper chaperone for 



































1.4 Copper Homeostasis in Saccharomyces cerevisiae 
The limited resources within the environment of yeast cells requires a competitive 
mechanism for the acquisition of copper, and a regulatory system to evade potentially toxic 
accumulation of this ion (Figure 1.2).  
 
1.4.1 Copper Uptake 
High affinity transporter proteins located at the plasma membrane have been identified to 
interact with and mediate the import of copper from the cell exterior to the cytosol.  The 
primary uptake route is through the transporter protein Ctr1 which contains three trans-
membrane domains arranged to form a central channel-like pore.23, 24  Methionine-rich 
motifs at the extracellular surface and the second transmembrane domain, and cysteine 
residues of the carboxyl-terminal domain have been proposed as sites of copper binding 
during translocation.  The lack of any features indicative of ATPase domains seen in active 
transporters leaves the question of how copper is driven across the membrane as unclear.  It 
has been suggested that observation of a Cu2+/K+ couple across the cellular membrane could 
be the driving force for an electrochemical gradient generating a Ctr1-mediated anti-port 
mechanism.25  Alternatively, high-affinity copper ion uptake has been measured as a 
temperature and ATP-dependent process26 which could indicate that Ctr1 forms higher 
order complexes that couple to ATPases.  In addition to Ctr1, S. cerevisiae also contains a 
second high affinity copper transporter Ctr3,27 a small cysteine-rich transmembrane protein 
reputed to have three domains similar to Ctr1. Interestingly, Ctr3 expression in the large 
majority of laboratory strains is absent due to the insertion of a transposable element at the 
promoter site.  This is most probably due to domesticated strains having been derived from 
a common ancestor in which Ctr3 was silenced by a chance transpon event.  Although Ctr1 
and Ctr3 function interchangeably in high-affinity copper transport, there is little sequence 
homology between these two proteins.  It has been observed that both transporters can 
function independently to provide high-affinity copper transport to yeast, although cells 
expressing both proteins have a distinct growth advantage over cells expressing either one 





The low-affinity transporter Fet4p functions as an Fe2+ permease which has been found to 
also facilitate Cu1+ transport across the cellular membrane.28  Copper ions imported by Fet4p 
were found to be metabolised in a similar manner to those imported by Ctr1.28  Copper also 
acts as a non-competitive inhibitor of iron uptake through Fet4p, indicating that binding of 
the two metal ions is not mutually exclusive and suggests that Fet4p has separate ligand 
sites for each substrate.   
 
1.4.2 Copper Reductases 
In aqueous solution, copper is found in the more stable Cu2+ oxidation state (Section 1.1.1), 
however copper transporters at the cell surface interact with the Cu1+ substrate.  
Metalloreductases at the plasma membrane have been identified which mobilize 
cytoplasmic electrons through the membrane and reduce Fe3+ to Fe2+.  It has also been 
shown that the metalloreductases Fre1 and Fre229, 30 implement the reduction of Cu2+ to 
Cu1+.23, 24  Considering that Cu1+ is easily oxidised to Cu2+ in the extracellular aerobic 
environment, it is feasible that a mechanism exists to protect Cu1+ in passage to the 
membrane transporters. 
 
1.4.3 Cellular Destinations of Copper 
Copper is required at three intracellular destinations, therefore, upon entry into the cell the 
metal is shuttled along one of three main intracellular transport pathways (Figure 1.2).  One 
route is transportation by the chaperone Atx1 to the membrane-bound P-type ATPase Ccc2 
at the trans-Golgi network31 for incorporation into the membrane-bound Fet3p oxidase, 
which participates in the uptake of iron at the cell surface.32  Another destination for copper 
is the mitochondria where it is incorporated into the cytochrome c oxidase (Cox) which is 
involved in the respiratory chain process of ATP production.  The role of the copper 
chaperone Cox17, originally thought to deliver copper to mitochondria, may actually be 
restricted to the delivery of copper to Cox within the intermembrane space.33  The 
metallochaperones Sco1 and Sco2 have also been indicated as playing a role in the delivery 
of copper to Cox17 within mitochondria.34  The third route is specific delivery to Cu,Zn-
superoxide dismutase (Sod1) by the copper chaperone for Sod1 (Ccs1)35 in both the 
cytoplasm, the mitochondrial intermembrane space and the nucleus, where it catalyses 
dismutation of the superoxide anion produced during aerobic respiration. 
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1.4.4 Copper Storage and Detoxification 
Intracellular copper is also sequestered by low molecular weight cysteine-rich 
metallothioneins which function to detoxify the cell and provide copper resistance.  In S. 
cerevisiae, the metallothioneins Cup120, 36 and Crs537 have been identified which tightly 
chelate the metal preventing solvent exposure and creating bound metal ions that are 
weakly exchangeable.  Cup1 consists of a 53-amino acid polypeptide that binds 8 copper ions 
through 10 cysteine residues suggesting cluster formation of the metal ion.18, 38  The 
metallothionein Crs5 was found to have a greater binding capacity for copper, 11-12 copper 
atoms ligated by ≤ 19 cysteine residues, and suggests that Csr5 may exhibit domain 
organisation as seen with mammalian metallothioneins.39 
 
Cellular vacuoles are also used to regulate cytosolic metal ion concentrations.  The process 
of accumulating alkali and transition metals, such as Ca2+, K+, Mn2+ and Fe2+, into the vacuole 
are documented40 whereas the process of copper import into the vacuole is yet to be 
identified.  Nevertheless, the copper transporter protein Ctr2 has been established to 
localise at vacuolar membranes and exports copper into the cytoplasm in times of copper 
deficiency.41      
 
1.4.5 Regulation of Copper Homeostasis 
The intracellular copper pathways are controlled through copper-sensitive transcriptional 
regulators in order to maintain a steady-state balance of intracellular copper. When the 
extracellular copper concentration is in excess, the transcription factor Ace1 is activated to 
induce expression of the metallothioneins Csr5, Cup1 and the redox protein Sod1.37, 42, 43  
Copper activation occurs through the formation of polynuclear Cu1+ clusters by Ace1 
cysteine residues44 which stabilise a specific conformation enabling Ace1 to bind with a 
response element of its target gene.45  The response element is a short DNA sequence within 
the promoter region of the gene and regulates the transcription of genes. The transcriptional 
activator Mac1 is associated with the copper uptake proteins Ctr1, Ctr2, Ctr3 and the 
metalloreductase Fre1.  Structurally, Mac1 exhibits an amino-terminal DNA binding domain 
and a carboxyl-terminal that contains two cysteine-rich copper binding motifs which bind up 
to eight copper ions as a copper-thiolate cluster and are thought to function as direct copper 
sensors. 27, 46  Under low levels of copper, Mac1 surveys the intracellular copper milieu and 
regulates expression of associated proteins depending on cellular needs by interacting with 
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the promoters of target genes.  When intracellular copper levels rise, copper binds to Mac1 
stimulating an interaction between the DNA binding domain and the cysteine-rich terminus, 
thereby masking the activation domain and repressing its target genes.29, 47-49  Mac1 also has 
an additional mode of regulation which is specific for copper in conditions of high 
intracellular copper concentration. In this circumstance the copper transporters are no 
longer useful to the cell and the transcription factor Mac1 undergoes proteolytic 
degradation.50 This completely eliminates the expression of the copper transporters and 
serves as a defence mechanism to avoid excessive copper accumulation.  In addition to 
transcriptional regulation, Mac1 has also been linked to a unique post-translational 
mechanism to control copper uptake by regulating the degradation of its target gene 
product.51  Upon exposure to excess extracellular copper, the high-affinity transporter Ctr1 is 
rapidly and specifically degraded at the plasma membrane without internalisation or 
delivery to the vacuole.52 Ctr1 degradation was found to occur only when Mac1 is 
expressed.53, 54Two possible roles of Mac1 have been proposed in Ctr1 degradation, the first 
proposes that Mac1 activates a gene that encodes the protease which degrades Ctr1. The 
second is that Mac1 recruits a protease or acts as a protease itself, however Mac1 is located 
in the nucleus55 while Ctr1 degradation occurs at the membrane.52 Nonetheless, truncated 
Mac1 has been found in the cytosol55 and Mac1 itself undergoes degradation in response to 
high copper levels. 
 
1.5 Mammalian Copper Homeostasis 
In mammals, copper transport pathways require a higher order of coordination than yeast 
since transportation can occur through the blood, and specific areas such as the brain and 
heart have higher demands for copper.56  The brain is one of the most energy-demanding 
tissues in the body57 and the primary source of ATP is the electron transfer train in the 
mitochondria.  The final complex in the chain is COX, whose subunits require copper.58 
Similarily, >95% of ATP production in the heart is produced by oxidative phosphorylation in 
the mitochondria.59 The principal use of energy by the heart is to fuel contractions, followed 
by the operation of several ion pumps.60, 61 
 
Although, on a cellular level the proteins associated with the human copper transfer 
pathways show a large degree of similarity to those of yeast.  In humans, copper enters the 
cytosol through the same mechanism as that in yeast, through the high-affinity transporter 
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CTR1 at the plasma membrane.    CTR1 is also located at intracellular vesicles and increased 
copper levels result in the re-localisation of CTR1 from the membrane to vesicles.62  The 
same three intracellular destinations for copper exist in humans as in yeast.  The chaperone 
HAH1 (yeast Atx1 homologue) transports copper to the ATPases ATP7A and ATP7B 
(equivalent to yeast Ccc2) at the trans-Golgi network for incorporation into cuproenzymes 
such as ceruloplasmin63, 64  in the secretory pathway.65  The importance of these transporters 
in copper homeostasis has been highlighted by genetic diseases, which are a result of 
incorrect protein function. Mutations associated with ATP7A results in Menkes disease 
whereas mutations of ATP7B result in Wilson’s disease (see section 8.1.3).   
In humans, copper is also required by COX in the mitochondria, and homologues of the yeast 
chaperones involved in copper delivery also exist; COX17, SCO1 and SCO2.66   The route of 
copper delivery in humans to SOD1 corresponds to that in yeast and is achieved by CCS1.35  
Mutations and incorrect post-translational modifications of SOD1 have been linked to 
amyotrophic lateral sclerosis (see section 1.6.5).67, 68 
 
1.6 Structure and Catalytic Action of Cu,Zn-Superoxide Dismutase 
Cu,Zn-Sod1 plays an important role in antioxidant defence by scavenging superoxide 
radicals.  The major source of intracellular superoxide is from ATP production in the 
mitochondria as a by-product of oxygen metabolism.69 
 
1.6.1 Protein Structure of Cu,Zn-Superoxide Dismutase 
Eukaryotic Sod1 proteins are highly conserved from primary to quarternary structure and are 
comprised of two identical subunits forming a dimeric protein.  Each subunit consists of a β-
barrel composed of eight antiparallel β-strands,70 and contains one Cu2+ ion and a Zn2+ ion.  
Activity measurements have shown that there is no cooperativity between subunits, 
however monomeric Sod1 formed by disruption of the quarternary structure by residue 





1.6.2 Active site of Cu,Zn-Superoxide Dismutase 
The zinc ion is completely buried in the Sod1 protein whereas the copper ion sits at the 
bottom of the active site channel.72  The copper ion is solvent exposed and interacts with a 
water molecule at the axial position which is linked to the bulk solvent by a chain of well-
ordered water molecules.73  The edge of the active site channel is constituted by charged 
residues which provide a positive electrostatic field that drives the superoxide anion towards 
the copper ion.  The copper ion is bound in a distorted square planar coordination by four 
histidine residues (His44, His46, His61, His118) and the zinc ion is coordinated by three 
histidine residues (His61, His69, His78) and an aspartic acid residue (Asp81) in a distorted 
tetrahedral geometry (Figure 1.3).74, 75 The distinguishing structural property of this active 





Figure 1.3. The structure of S. cerevisiae Cu,Zn-Sod1 and the active site with copper and zinc 
bound. (A) Crystal structure of Cu,Zn-Sod1, the metal-binding residues are shown in red and 
the Cu2+ (gold) and Zn2+ (blue) ions are shown as spheres. (B) The coordinating residues at 
the Cu2+ (gold sphere) and Zn2+ (blue sphere) ions are shown as sticks. Images created with 














1.6.3 Catalysis Mechanism 
The catalytic action of Sod1 involves the disproportionation of superoxide to molecular 
oxygen and hydrogen peroxide (Scheme 1.1).  Kinetic studies have indicated that the copper 
ion of Sod1 is cyclically reduced and oxidised between the +1 and +2 oxidation states in two 
irreversible reactions (Scheme 1.1).76-78 
 
02
− +  𝐶𝑢2+  →  𝑂2 +  𝐶𝑢
+ 
2𝐻+ +  𝑂2





Structures of Sod1 alone and in complex with the product H2O2 bound4 and studies 
indicating an inner-sphere mechanism79 have helped produce a unified general mechanism 
for Sod1 that takes into consideration steric restrictions at the copper site (Figure 1.4).4, 11   
Superoxide radicals have been shown to undergo spontaneous disproportionation to 
molecular oxygen and hydrogen peroxide in solution, however this requires the interaction 
of two superoxide molecules and is therefore second-order with respect to superoxide 
concentration.  In contrast, catalysis of this reaction with Sod1 is first-order with respect to 
superoxide concentration and the reaction rate is only limited by the rate of diffusion.6  It 








Figure 1.4.  The mechanism showing how Sod1 catalyses the dismutation of superoxide into oxygen and hydrogen peroxide. (A) A superoxide anion 
displaces a water molecule in the axial position at the Cu2+ site of Sod1 and forms a hydrogen-bond with  Arg141. (B) Superoxide is oxidised by Cu2+ 
via inner-sphere electron transfer resulting in 02 and Cu1+-Sod1, cleavage of the Cu-N (His61) bond and protonation of His61. (C) A second superoxide 
anion binds to Cu1+ and is stabilised by hydrogen bonds to Arg141 and His61. (D) His61 donates a proton to superoxide prior to, or simultaneously 
with, inner-sphere electron transfer from Cu1+ and hydrogen peroxide is released following the addition of another proton (shown in green). The 
































1.6.4 Cu,Zn-Superoxide Dismutase Maturation 
Maturation of Sod1 to an enzymatically active form requires the acquisition of both copper 
and zinc, and the formation of a structurally important disulfide bond between Cys57 and 
Cys146.80  Exposure of apo-SOD1 to Zn2+ ions in vitro generates a mixture of E,Zn-Sod1 and 
Zn,Zn-SOD1 indicating that SOD1 is unable to site-selectively bind Zn2+ since a second ion is 
also bound to the Cu2+ site.81  However, studies have shown that SOD1 is capable of site-
specifically recruiting Zn2+ in vivo.82  The copper chaperone for superoxide dismutase has 
been implicated in the formation of the disulphide bond in SOD1, and D3 of human CCS1 
has been found responsible for this formation in SOD1 in vitro.83  The stability of the 
structural disulphide in SOD1 is particularly interesting since the cytosol is a reducing 
environment due to the presence of excess reduced glutathione over the oxidised form.84  
These are important steps for the correct functioning of the enzyme and prevention of 
misfolding and aggregation of the protein.80, 85  
 
1.6.5 Link to Amyotrophic Lateral Sclerosis 
In humans, a link has been drawn between the neurodegenerative disorder familial 
amyotrophic lateral sclerosis (ALS) and the SOD1 protein.  Symptoms include muscle 
atrophy due to the degeneration of motor neurons, and cognitive dysfunction such as 
language defects, repeating gestures and loss of inhibition.  The clinical course of ALS is 
progressive and typically causes death within 3 – 5 years of onset, mostly due to respiratory 
failure.86  The first causative mutations were found within the gene encoding SOD1,87, 88 
since then many more SOD1 mutations have been described, although pathogenicity has 
not been attributed to all.  Initially, the loss of SOD1 activity found in patients with ALS and 
mutations throughout the SOD1 gene suggested a mechanism whereby a loss of function 
occurs, however, later research has shown that a toxic gain of function mechanism is the 
actual contributor to ALS.89  The distinct lack of SOD1 activity in ALS patients has been 








1.7 The Copper Chaperone for Cu,Zn-Superoxide Dismutase 
The Sod1 copper chaperone Ccs1 is not only responsible for delivering copper directly to its 
target protein, but also activating Sod1 to its enzymatically active state. 
 
1.7.1 The Structure of Ccs1 
Structural studies with yeast Ccs1 have shown that the ≈ 30 kDa protein is comprised of 
three distinct domains which are thought to have specific functions.  The N-terminal domain 
(D1) consists of 70 amino acid residues arranged in a βαββαβ fold and contains an MXCXXC 
(Cys17 and Cys20) copper binding site.92  This domain is homologous to yeast Atx1, human 
HAH1 and bacterial CopZ since all feature the same βαββαβ fold and copper binding motif 
(Figure 1.5).  The central polypeptide domain (D2) of Ccs1 contains 123 residues arranged in 
β-barrel folds and is structurally homologous to Sod1, although the sub-loop which binds 
zinc in Sod1 is not present in Ccs1 (Figure 1.6).92  Human CCS1 contains the zinc-binding sub-
loop seen in SOD1 however the primary function of this site is structural.93  Interestingly, the 
most highly conserved sequences between D2 of Ccs1 and Sod1 are those known to be 
involved in facilitating Sod1 dimerisation, such as the residues whose peptide bonded 
backbone is involved in forming four hydrogen bonds at the Sod1 dimer interface (Ccs1 = 
Gly137 and Gly187, Sod1 = Gly52 and Gly115).74  The same four hydrogen bonds seen in the 
Sod1 dimer are present in the Ccs1-Sod1 complex, however Leu152 involved in the Sod1 
dimer is Arg217 of Ccs1 in the Ccs1-Sod1 complex (Figure 1.7).75  This suggests that the 
function of D2 is recognition and formation of a Ccs1-Sod1 complex preceding copper 
insertion.  Although D2 is required for heterodimer formation, this domain alone is not 
sufficient and interactions with D3 have also been implicated.94  The C-terminal domain (D3) 
of Ccs1 is a short random-coil polypeptide unique to this chaperone, and contains a CXC 
(Cys229 and Cys231) motif.75  These structural domains are conserved across the majority of 
eukaryotic copper chaperones for Cu,Zn-superoxide dismutase (Figure 1.8), however the 
CCS proteins of Melanogaster drosophila95 and Schizosaccharomyces pombe96 have been 










Figure 1.5. A comparison of the structure of domain 1 of Ccs1 to those of the Atx1-family of copper metallochaperones. The structures of S. 
cerevisiae Ccs1 (A) in which only D1 (magenta) and D2 (blue) are observed, S. cerevisiae Atx1 (B), H. sapien HAH1 (C) and E. Hirae CopZ (D). All 
proteins contain a 𝛽α𝛽𝛽α𝛽-fold and MXCXXC sequence motif (D1 OF Ccs1). The metal-binding Cys residues are shown in yellow. Images 












Figure 1.6. A comparison of the structure of domain 2 of Ccs1 to domain 2 of CCS1 and Sod1. Crystal structures of S. cerevisiae Ccs1 (A) in 
which only D1 (magenta) and D2 (blue) are observed, H.sapien CCS1 (B) in which only D2 is observed and S. cerevisiae Cu,Zn-Sod1 (C). The 
metal-binding Cys residues are shown in yellow, the His residues in red and the Cu2+ (gold) and Zn2+ (blue) ions are shown as spheres. Images 














Figure 1.7.  A comparison of the hydrogen bond interactions between the Sod1 homodimer and Sod1-Ccs1 heterodimer interfaces. The 
residues involved with hydrogen bonding of the (A) S. cerevisiae Sod1 homodimer (Sod1 monomer residues shown in dark or light green), and 





S.pombe             ----------MFEVEYLIK------DCDDVNKNTLEQEFQDLNIEDWKWDAATGQLIVKG 44 
S.cerevisiae        -----MTTNDTYEATYAIPMHCE--NCVNDIKACLKN---VPGINSLNFDIEQQIMSVES 50 
D.melanogaster      --------MSSIKIEFAVQMRRGDESYAGALRSA------LDGVGQVEIDTQEGRVIIQT 46 
R.norvegicus        MASKSGDGGTMCALEFTVQMSCQ--SCVDAVHKTLKG---AAGVQNVEVQLENQMVLVQT 55 
M.mulatta           MASDSGNQGTLCTLEFAVQMTCQ--SCVDAVRKSLQG---VAGVQDVEVHLENQMVLVHT 55 
H.sapien            MASDSGNQGTLCTLEFAVQMTCQ--SCVDAVRKSLQG---VAGVQDVEVHLEDQMVLVHT 55 
P.troglodytes       MASDSGNQGTLCTLEFAVQMTCQ--SCVDAVRKSLQG---VAGVLDVEVHLEDQMVLVHT 55 
B.taurus            MASDSEDRGTACTLEFAVQMTCQ--SCVDAVRTSLQG---IAGIQSVEVQLENQMVLVQT 55 
E.caballus          MALDSGDSGTACTLEFAVQMTCQ--SCVDAVRTSLQG---VAGVQSVEVQLENQMVVVQT 55 
 
 
S.pombe             SVSPSKVLRRLENATSKPILIRGASNKE-SGVSIL---YEANEDITQIPKVYGLCRFIPT 100 
D.melanogaster      QRPWSEIQDKIEATGVRAV-LSGFGGQSAVALIN------TTGSVVDKTPIQGVVRFTTI 99 
S.cerevisiae        SVAPSTIINTLRNCGKDAI-IRGAGKPNSSAVAILETFQKYTIDQKKDTAVRGLARIVQV 109 
R.norvegicus        TLPSQEVQALLESTGRQAV-LKGMGSSQLKNLGA------AVAIMEGSGTVQGVVRFLQL 108 
M.mulatta           TLPSQEVQALLEGTGRQAV-LKGMGSDQLHNLGA------AVAILGGPGTVQGVVRFLQL 108 
H.sapien            TLPSQEVQALLEGTGRQAV-LKGMGSGQLQNLGA------AVAILGGPGTVQGVVRFLQL 108 
P.troglodytes       TLPSQEVQALLEGTGRQAV-LKGMGSGQLQNLGA------AVAILGGSGTVQGVVRFLQL 108 
B.taurus            TLPSQEVQALLEGTGRQAV-LKGMGSGLLQNLGA------AVAILGGPGPVQGVVRFLQL 108 
E.caballus          TLPSQEVQAILEGTGRQAV-LKGMGSGILENLGA------AVAILGGPGPVQGVVRFLQL 108 
 
 
S.pombe             EEK----IFLDLIATQLLPNREYTGLVTISGDISRGLKSAGDSLVTLFNA---------- 146 
D.melanogaster      TADKKPGVVVDGVVDGL-SPGLHGLHIHESGDTSAGCSSVGEHYNPRQSPHGSPAAGAEE 158 
S.cerevisiae        GEN---KTLFDITVNGVPEAGNYHASIHEKGDVSKGVESTGKVWHKFDEPIECF------ 160 
R.norvegicus        SSE---LCLIEGTIDGL-EPGLHGLHVHQYGDLTKDCSSCGDHFNPDGASHGGPQD--TD 162 
M.mulatta           SPE---RCLIEGTIDGL-ESGLHGLHVHQYGDLTNNCNSCGDHFNPDGASHGGPQD--SD 162 
H.sapien            TPE---RCLIEGTIDGL-EPGLHGLHVHQYGDLTNNCNSCGNHFNPDGASHGGPQD--SD 162 
P.troglodytes       TPE---RCLIEGTIDGL-EPGLHGLHVHQYGDLTNNCNSCGNHFNPDGASHGGPQD--SD 162 
B.taurus            TPE---RCLIEGTIDGL-QPGLHGLHVHQFGDLTRNCNSCGDHFNPDGMSHGGPQD--SE 162 
E.caballus          TPE---RCLIEGTIDGL-EPGPHGLHVHQFGDLTRNCNSCGDHFNPDGTSHGGPQD--SE 162 
                      
 
S.pombe             -NSNEQGKIVL-------DKEVSGSLPNW--IGHCFVLKCVD----------------DS 180 
D.melanogaster      RHAGDLGNIRADENGRATFRFVDPVLEVWDIIGRAVVLTANADDLGRGGNDQSLIDGNSG 218 
S.cerevisiae        -NESDLGKNL-----YSGKTFLSAPLPTWQLIGRSFVISKSLNHPEN---EPS----SVK 207 
R.norvegicus        RHRGDLGNVHAEASGRATFRIEDKQLKVWDVIGRSLVVDEGEDDLGRGGHPLSKVTGNSG 222 
M.mulatta           RHRGDLGNVHADADGCAIFRMEDEKLKVWDVIGRSLVIDEGEDDLGRGGHPLSKITGNSG 222 
H.sapien            RHRGDLGNVRADADGRAIFRMEDEQLKVWDVIGRSLIIDEGEDDLGRGGHPLSKITGNSG 222 
P.troglodytes       RHRGDLGNVRADADGRAIFRMEDEQLKVWDVIGRSLIIDEGEDDLGRGGHPLSKITGNSG 222 
B.taurus            RHRGDLGNVRADEDGRAVFRIEDEQLKVWDVIGRSLVIDEGEDDLGRGGHPLSRITGNSG 222 
E.caballus          RHRGDLGNVHADAEGRVVFRIEDEQLKVWDVIGRSLVIDEGEDDLGQGGHPLSKITGNSG 222 
                      
 
S.pombe             DSATMGIISRSAGLGQNTKQICACTGKSLWTEHAELKSVNEGSSCCSKKDSSPSEKPSCC 240 
D.melanogaster      ERIACGIIARSAGILENFKRICACDGVTLWDERNKPLAGKDRSQ--------KL------ 264 
S.cerevisiae        DYSFLGVIARSAGVWENNKQVCACTGKTVWEERKDALANNIK------------------ 249 
R.norvegicus        KRLACGIIARSAGLFQNPKQICSCDGLTIWEERGRPIAGQGRKD--------SAQPPAHL 274 
M.mulatta           QRLACGIIARSAGLFQNPKQICSCDGLTIWEERGRPIAGKGRKE--------SAQPPAHL 274 
H.sapien            ERLACGIIARSAGLFQNPKQICSCDGLTIWEERGRPIAGKGRKE--------SAQPPAHL 274 
P.troglodytes       ERLACGIIARSAGLFQNPKQICSCDGLTIWEERGRPIAGKGRKE--------SAQPPAHL 274 
B.taurus            ERLACGIIARSAGLFQNPKQICSCDGLTIWEERGRPIAGQGRKE--------PAQPPAHL 274 
E.caballus          ERLACGIIARSAGLFQNPKQLCTCDGLTIWEERGRPIAGKGRKE--------PAQPAAHL 274 
                     
 
S.pombe             SQEKKSCCSSKKPSCCSQEKKGCCSTEKTSCCSQEKKSCCTSEKPSCCSNGKSTVCA 297 
D.melanogaster      --------------------------------------------------------- 264 
S.cerevisiae        --------------------------------------------------------- 249 
R.norvegicus        --------------------------------------------------------- 274 
M.mulatta           --------------------------------------------------------- 274 
H.sapien            --------------------------------------------------------- 274 
P.troglodytes       --------------------------------------------------------- 274 
B.taurus            --------------------------------------------------------- 274 
E.caballus          --------------------------------------------------------- 274 
 
Figure 1.8. Sequence alignment of the copper metallochaperone for Cu,Zn-superoxide 
dismutases from a range of species. Cys residues which bind copper ions are highlighted in 
yellow and His residues which bind zinc ions are highlighted in red. Protein sequences 
sourced from UniProt100 and aligned with Clustal Omega.27, 101  
Protein sequence Accession Numbers: Schizosaccharomyces pombe Q10357, Drosophila 
melanogaster Q9BLY4, S. cerevisiae P40202, Rattus norvegicus Q9JK72, Macaca mulatta F7FL64 , 




1.7.2 The Mechanism of Sod1 Activation 
The main focus of research has centred on the human and yeast chaperones, however there 
is major disagreement regarding the mechanism of Cu,Zn-superoxide dismutase activation.  
Studies performed in vivo with human CCS1 have shown that the CXXC motif of D1 is 
essential for SOD1 activation.102  This is consistent with the higher affinity of the CXXC motif 
of D1 for copper compared to the CXC motif in D3.103  However, investigations relying on 
SOD1 activity assays cannot identify the independent occurrence of copper insertion and 
disulphide formation.  The use of nuclear magnetic resonance (NMR) and electrospray 
ionization mass spectrometry (ESI-MS) has allowed the actions of copper transfer and 
disulphide formation to be studied independently.  These techniques have suggested that 
D1 of CCS1 is essential for copper insertion in humans, and D3 is responsible for the 
formation of the disulphide in SOD1.83  The mechanism of human SOD1 activation by CCS1 
has been suggested (Figure 1.9).83  Firstly, immature SOD1 (E,E-SOD1SH, notation indicates 
empty metal sites and reduced disulfide) recruits zinc, then forms a heterodimeric complex 
with copper loaded CCS1.  D1 of CCS1 then transfers the copper ion to SOD1 to form the 
fully metallated Cu,Zn-SOD1SH, followed by disulphide isomerization from D3 to Cys57 and 
Cys146 of SOD1.  Lastly, the heterodimeric complex dissociates releasing mature Cu,Zn-
SOD1S-S and CCS1 which is able to activate further SOD1 molecules. 
 
This mechanism is completely contradicted by investigations with yeast Ccs1.  D1 of yeast 
Ccs1 was found to be necessary for Sod1 activation only under copper limiting conditions, 
and the cysteine residues of the CXC motif in D3 have been determined as crucial for Sod1 
activation.104  This is compatible with the position of D3 as adjacent to the active site of 
Sod1 in the crystal structure of the Ccs1-Sod1 complex, and is therefore ideally positioned 
for copper transfer (Figure 1.10).75  Also, in this structure the metal binding site of D1 is ≈ 35 
Å from the SOD1 active site suggesting that D1 is not involved in direct copper insertion.  A 
disulphide bond is also observed between Sod1 Cys57 and Ccs1 Cys229 which could indicate 







Due to the flexibility and only partial structural organization of D3 it has been proposed that 
D3 is able to obtain copper from D1.105, 106  This has appeared feasible in both yeast Ccs175 
and human CCS1,107 and copper transfer has been observed between the human domains in 
partition experiments.103  Therefore the role of D1 would be expected to involve Cu1+ 
acquisition and transfer to D3 for insertion into SOD1, however the increased affinity of D1 




Figure 1.9.  The activation of human SOD1 by CCS1, (A) CCS1 recruits Cu1+. (B) E,Zn-SOD1SH 
forms a heterodimeric complex with Cu1+-CCS1. (C) D1 of CCS1 transfers Cu1+ to E,Zn-
SOD1SH. (D) A disulfide bond is formed within the CXC motif in D3 of CCS1 and a 
conformational change moves D3 of CCS1 into the vicinity of the SOD1 Cys residues. (E and 
F) Disulfide isomerization from D3 of CCS1 to Cu,Zn-SOD1SH. (G) The CCS1-SOD1 
heterodimeric complex dissociates releasing Cu,Zn-SOD1S-S and CCS1. (H) Cu,Zn-SOD1S-S 







Figure 1.10. The crystal structure of the heterodimeric complex between S. cerevisiae 
Ccs1 and a mutant Sod1 (His48 mutated to Phe).  (A) The location of Ccs1 copper-binding 
Cys229 and Cys231 in D3. (B) Disulfide bond between Cys229 of Ccs1 D3 and Cys57 of 
Sod1. (C) The location of Ccs1 D1 Cys17 and Cys20. The Sod1 monomer is shown in green, 
D1 of Ccs1 in magenta, D2 of Ccs1 in blue and D3 of Ccs1 in yellow. The metal-binding Cys 
residues are shown in yellow, the His residues in red and the Zn2+ (blue) ion is shown as a 



















1.8 The Copper Chaperone Atx1 and its Target Protein Ccc2 
The chaperone Atx1 is responsible for delivering copper to the ATPase cation transporter 
Ccc2 located at the membrane of the trans-Golgi network.  Ccc2 facilitates the transport of 
copper into Golgi vesicles with the ultimate destination of the multicopper oxidase Fet3p 
which mediates high affinity iron uptake at the cell surface.32 
 
1.8.1 Structure of Atx1 and Ccc2 
Yeast Atx1 contains 72 residues arranged in a βαββαβ-fold, homologous to that seen in Ccs1 
and ferredoxin proteins.108  An MXCXXC motif (Cys15 and Cys18) is located at a comparable 
position to the one contained in Ccs1.  The oxidation state of the copper bound to Atx1 has 
been measured as Cu1+ and is positioned within a trigonal geometry, most probably the two 
sulfurs of the MXCXXC motif and a third ligand, possibly O, N or S from another amino 
acid.31 
The target protein of Atx1, the Ccc2 transporter, has an overall structure containing four 
cytoplasmic domains spread across eight membrane-spanning domains.109  The majority of 
studies have focused on the amino terminal domain (Ccc2a) as this is the location of copper 
transfer from Atx1.  Ccc2a contains 72 amino acid residues and shares the same βαββαβ-
fold arrangement as Atx1.110  Ccc2 is homologous to the ATP7A/ATP7B transporters in 
humans, although Ccc2a contains two MXCXXC metal binding motifs similar to that in Atx1, 
ATP7A/ATP7B both contain six of the same metal binding motifs.111 
 
1.8.2 Copper Transfer to Ccc2 
Specific residues along the surfaces of Atx1 and Ccc2a are thought to be the basis of 
recognition between these partner proteins.  Atx1 has a number of basic lysine residues 
along its surface which complement the acidic glutamate and aspartate residues at the 
surface of Ccc2a.108, 110  The electrostatic forces between these residues allow Atx1 to ‘dock’ 
with Ccc2a and provide the correct orientation of binding sites for direct copper transfer.  
This theory is backed up by a mutagenic study which showed that the loss of lysine residues 
at the surface of Atx1 caused decreased delivery of copper to Ccc2a.112  NMR investigations 




proposed the formation of copper bridged 2- and 3-coordinate intermediates between an 
Atx1-Ccc2 heterodimeric complex (Figure 1.11).31  A similar process has been suggested for 
the human homologues HAH1 and the transporters ATP7A and ATP7B.113  Interestingly, it 
has been claimed that the thermodynamic gradient of copper transfer between Atx1 and 







Figure 1.11.  A proposed mechanism of Cu1+ transfer between Atx1 and Ccc2a  in S. 
cerevisiae. The exchange of Cu1+ involves the stepwise formation of two- and three-
coordinate Cu1+-bridged intermediates. The scheme is adapted from reference 31 and 















1.8.3 Associations with Human Diseases 
The human homologues of the Atx1 target Ccc2 are ATP7A and ATP7B.  A mutation in the 
ATP7A gene has been shown to cause the X-linked recessive Menkes disorder, of which 
onset typically begins in infancy and many affected newborns do not live past the age of 3 
years. 115  The phenotypes of Menkes disease includes low muscle tone, seizures, 
progressive neurological deterioration, poor temperature regulation and characteristic kinky 
hair.116,117  As a result of the mutation, copper distribution is disrupted resulting in 
accumulation in some tissues, whereas the brain and other tissues have unusually low 
levels. One important location of ATP7A is in the intestines where it is required for the 
absorption and transport of copper into the circulation.  ATP7A is also located at the trans-
Golgi network and is essential for transporting copper from the cytosol into the lumen for 
incorporation into secreted copper-requiring enzymes.8-10, 115  The disease phenotypes are 
caused by mutational inactivation of ATP7A and inability of dietary copper to be absorbed 
and supplied to essential enzymes. The decreased supply of copper reduces the activity of 
copper-dependent proteins, reduced lysyl oxidase activity has been linked to hair and 
connective tissue abnormalities and neurological degeneration is suggested to be caused by 
reduced activity of neuronal cytochrome c oxidase.118  
Mutations in the gene for ATP7B is linked to the autosomal recessive disorder Wilson’s 
disease.119  This is characterised by the accumulation of copper in the liver and brain119 and 
a failure to excrete copper from the liver to bile. This results in toxic accumulation of the 
metal which kills hepatocytes and inadvertently releases copper into the central nervous 
system.120  Symptoms present as liver disease and neurological or psychiatric issues such as 
parkinsonism, seizures and behavioural changes.  Visible dark rings that circle the iris of the 
eye are often seen in affected patients, known as Kayser-Fleischer rings, and these are a 
diagnostic sign of the disease. 
 
1.9 Bacterial Copper Homeostasis 
It is currently thought that bacterial cells have a lower requirement for copper than 
eukaryotes.  Understanding the routes of copper transport in bacteria is further complicated 
by the expectation of distinctive pathways and proteins between Gram-positive and Gram-




components involved in copper trafficking within Gram-positive and Gram-negative 
bacteria; a copper exporter, a copper chaperone and a copper-responsive transcriptional 
regulator. 
The mechanism of copper import into Gram-positive bacteria is not fully understood. 
Several systems have been proposed, such as the action of YcnJ121 and ZosA23 as copper 
importers in Bacillus subtilis, however further evidence is required. The trafficking of copper 
to required destinations and the prevention of toxicity in the cytoplasm is undertaken by 
copper chaperones such as CopZ of Enterococcus hirae.25  CopZ is an 8-kDa protein with a 
βαββαβ-fold and MXCXXC Cu1+-binding motif  that are both found in the yeast proteins Atx1 
and Ccs1, and the human protein HAH1 (Figure 1.5). Also, some methane-oxidising bacteria 
(methanotrophs) that oxidise methane to methanol secrete copper-binding peptides named 
methanobactins which mediate copper entry into the cell.122, 123  In E. coli (Gram-negative), 
copper resistance is attributed to two copper efflux systems, the Cue (copper efflux) and 
Cus (copper sensing) systems.  The Cue system is the primary copper export route, whereas 
the Cus system is up-regulated under extreme levels of copper stress in order to transport 
copper across the cell envelope to the extracellular space.124  The Cus system mediates the 
efflux of copper from the cytoplasm to the periplasm by the P-type ATPase CopA,125 which 
shares similarities to the ATP7A and ATP7B transporters in humans, and Ccc2 in yeast.  
Further copper tolerance is attributed to a multi-copper oxidase, CueO, which oxidises Cu1+ 
to Cu2+ in the periplasm, thereby decreasing the rate of copper entry into the cytoplasm.126  
Both CopA and CueO are upregulated when cells are exposed to even low levels of 
copper.124, 127  The Gram-positive bacteria Bacillus subtilis has also been shown to contain 
the metallochaperone CopZ which has a similar structure to yeast Atx1 and is thought to 
transfer copper to the transporter CopA.128 
 
1.10 Cross-Talk Amongst Copper Pathways 
Atx1 and Ccs1 are both cytosolic chaperones.  The mechanism of how cells distribute copper 
between the various trafficking pathways is yet to be understood, the entry of copper into a 
cell is known but how the ions are then allocated along a particular route can only be 
theorized.  Copper recruitment by the Ccs1 and Atx1 chaperones may occur from 




is the case then the distribution of copper would depend on the specific affinity of the 
chaperones and their abundance within that location.  Another possibility is that the 
chaperones actively collect copper from the Ctr1 transporter.  In this scenario the 
distribution of copper would depend on preferential interactions at the chaperone-
transporter interface, resulting in a competition between Atx1 and Ccs1 for copper.  There is 
some evidence to support this mechanism as the exchange of copper between Ctr1 and 
Atx1 has been shown.130  There are similarities between Ccs1 and Atx1 that are not limited 
to the copper binding motif, such as the βαββαβ-fold structure which is homologous to Atx1 
and Ccs1 D1.  This would suggest that they transfer or collect copper through a similar 
process, however, a study with chimeric genes have shown that Atx1 is unable to substitute 
for Ccs1 D1104 and each mechanism of copper insertion seem to differ.  
 
1.11 CCS-independent organisms 
Certain eukaryotic organisms can activate SOD1 independently of the copper chaperone, 
such as the roundworm Caenorhabditis elegans, in a process thought to involve glutathione.  
This process may be explained by an ability of the cysteine residues involved in disulphide 
formation to undergo oxidation more readily.131,132  In humans, it has been shown that SOD1 
activation is achieved in cell lines that are unable to express CCS1 and that SOD1 can also 
receive copper via glutathione.  In contrast, the Sod1 from yeast S. cerevisiae is unable to 
acquire copper independently of Ccs1, due to the presence of a proline residue near the C-
terminal of the Sod1 protein.133  This inability of S. cerevisiae to undergo Ccs1-independent 
activation of Sod1 makes it an ideal system for studying the intricate copper pathways 
involving Sod1 and Ccs1 because any alterations will not be masked by a basic level of 
activation independent of Ccs1. 
 
1.12 The Use of Mutations to Investigate Cu1+ Affinities 
The use of mutations to investigate the function of proteins has a long history in the 
biological sciences. One of the most direct ways to discover the function of a protein 
encoded by a particular gene is to observe what happens after the introduction of specific 
changes to its gene. Due to the interruption of cellular processes, mutations can be used to 




protein that has more than one binding site, as is the case with Ccs1, small changes can 
afford the ability to focus on a single binding-site in isolation. Such changes, such as to single 
amino acids, can be achieved with site-directed mutagenesis. By altering only selected 
amino acids using this technique, the effect on protein folding, interactions with other 
proteins and enzymatic function can be minimised if required. 
In order to study the importance of the D1 Cys17 and Cys20, and D3 Cys229 and Cys231 
residues in Ccs1, their mutation would be of great use. By removing the ability of the Cys-
containng motif of one domain (D1 or D3) to bind Cu1+ or to form disulfide bonds, the 
remaining domain can be studied in isolation. Previously, the mutation of one or both of 
these cysteine residues in either D1 or D3 have been performed to study human CCS1 and S. 






Table 1.1. Mutations of Ccs1/CCS1 in the literature starting with the most recent. A range of 
single and double amino acid substitutions in the yeast and human proteins that have been 
studied previously. 
 
Protein Mutation(s) Year, Reference 
Human CCS1 
Cys22 and Cys/25 to Ser in D1 
Cys244 and Cys246 to Ser in D3 
2012, 103 
Yeast (S. cerevisiae) Ccs1 
Cys17 and Cys20 to Ser in D1 
Cys229 and Cys231 to Ser in D3 
2008, 95 
Human CCS1 
Cys22 to Ala in D1 
Cys244 to Ala in D3 
Cys22 and Cys25 to Ala in D1 
Cys244 and Cys246 to Ala in D3 
2007, 134 
Human CCS1 
Cys22 to Ser in D1 
Cys244 to Ser in D3 
Cys22 and Cys25 to Ser in D1 







The side chain of serine is iso-structural to cysteine but includes a hydroxyl (OH) instead of a 
thiol (SH) group (Figure 1.12). Serine is more hydrophilic than cysteine and is unable to form 
disulfide bonds. Also, due to the higher electronegativity and lower polarizability of serine 
compared to cysteine, the deprotonated hydroxyl group of serine is a ‘hard’ Lewis base and 
will bind very weakly, if at all to ‘soft’ Cu1+ ions (see section 1.1.2). Therefore, the 
replacement of cysteine with serine in the CXXC (D1) and CXC (D3) motifs of Ccs1 could 




Figure 1.12. The structures of the amino acids cysteine and serine. The structures show the 


















1.13 The Affinity of Proteins for Metals 
To develop a detailed understanding of how copper is driven along complex intracellular 
pathways the molecular basis of metal binding needs to be clarified.  A fundamental 
property of metallo-proteins is their tendency to associate with specific metal ions.  Known 
as the affinity of a protein P for a particular metal M, this is defined by the association 
constant Kb (Equation 1.2).136  Measurement of the affinity can provide a quantitative 
indication of metal selection and allows proteins to be compared by this characteristic.  
𝑀 +  𝑃 ⇌  𝑀𝑃 𝐾𝑏 =  
[𝑀𝑃]
[𝑀][𝑃]
 (Equation 1.2) 
 
1.13.1 The Complications of Measuring Protein Affinity 
The components of copper-trafficking systems present a variety of issues in a laboratory 
environment.  Many copper-binding proteins, such as Ccs1 and Atx1, employ the amino acid 
cysteine to coordinate the metal ion, however the thiol side-chains of cysteines are readily 
oxidised to the disulfide which only binds metals very weakly.  The thiol status of these 
proteins must be fully reduced in order to provide an accurate interaction with the metal.  
Also, Cu1+ is unstable in aqueous solution and prone to disproportionation to the more 
stable Cu2+ (see section 1.1.1), thus it is crucial to review copper samples to determine the 
oxidation state of the metal in use. The use of specialist anaerobic equipment and sensitive 
analysis of each constituent can negate these issues, however experiments still require a 
highly vigilant mind-set even with these strategies in place.  
Accurate estimation of Cu1+ protein affinities has proven difficult, which is highlighted by the 
range of values that been reported previously.  For example, the affinity of HAH1 for Cu1+ 
has been reported as ranging from 105 to 1018 M-1 (Table 1.2). 
The problems with reliable evaluation are due to a variety of factors associated with 
particular methods and techniques that must be effectively considered.  The lowest 
reported Kb value for HAH1 (105 M-1, Table 1.2) was measured by the method of isothermal 
titration calorimetry (ITC).  This is a direct method that measures the thermodynamics of 
interactions between two or more molecules in solution.  It is viable that one ITC 
experiment can quantify the binding stoichiometry, affinity constant (Kb) and binding 




change (ΔSo) of a particular reaction.  The ability to determine a complete thermodynamic 
picture of a binding event makes ITC a particularly useful technique, however major 
considerations are required to ensure careful analysis of experimental data since titration 
calorimeters measure the sum of the heat associated with all processes occurring upon 
titrant aliquots.  Analysis of the data must include accurate corrections for precipitation, 
hydrolysis, redox reactions, metal ion competition with protons and interactions with the 
buffer.21, 22  Also, adventitious binding of metal ions to the amino acid side-chains on protein 
surfaces is typical with Kb values as low as 106 M-1, therefore it is improbable that proteins 




Table 1.2. Literature stated Cu1+  affinity (Kb) values of various metallo-proteins. The affinity 





pH Reference Method 
HAH1 (Atox1) 
Human 
2.5 x 105 6.5 100 ITCa 
3.5 X 1010 7.5 96 Competition with BCA 
1.7 x 1016 7.5 137 ESI-MSb, competition with DTT 
3.9 x 1018 7.0 138 Competition with BCS 
5.6 x 1017 7.0 139 Competition with BCS 
4.3 x 1017 7.0 140 Competition with BCS 
Atx1 
Yeast 
2.1 x 1018 7.0 138 Competition with BCS 
1019 8.0 141 Competition with BCS 
1016 6.0 19 Competition with BCS 
4.7 x 1017 7.0 140 Competition with BCS 
CCS1 
Human 
2.4 x 1015 7.5 137 ESI-MSb, competition with DTT 
5.5 x 1017 7.5 103 Competition with BCS 
Ccs1 
Yeast 
2.4 x 1017 7.5 103 Competition with BCS 
 
a Isothermal Titration Calorimetry 






1.13.2 Indirect Competition Method  
An alternative technique to measure a protein’s affinity employs the competition between 
two ligands for metal ions, one ligand being the protein in question and the other a suitable 
small molecular ligand.  This approach depends exclusively on the final equilibrium positions 
of the competition reaction, and is not affected by a lot of the issues associated with ITC.  
The process of complex formation does not affect the final equilibrium, the concentration of 
‘free’ metal is considered negligible at equilibrium and the potential problems of metal 
hydrolysis and metal ions bound by buffers is prevented. 
 
1.13.3 Ligand Choice 
There are a variety of molecules that are able to bind Cu1+ however the selection of a 
suitable competitive ligand is crucial for successful competition.  If the affinity of the ligand 
for Cu1+ is too low it will be unable to compete with the protein for the metal, similar 
problems arise if the ligand affinity is too high, therefore it is necessary to select a ligand 
with an affinity in the same region as the protein. 
Dithiothreitol (DTT) is a small molecule (Figure 1.13) generally used as a reducing agent 
against thiolated DNA and protein disulfide bonds.  The two sulfur donors are able to bind 
suitable metal ions such as Cu1+ with stoichiometries being dependent on the reaction 
conditions.142  DTT has been used previously as a ligand for Cu1+ competition experiments,137 
however there are many problems associated with its use.  Among these is the susceptibility 
of DTT oxidation in air and the requirement of accurate binding stoichiometries, resulting in 
DTT being designated as an unsatisfactory Cu1+ affinity reference.138 
Two popular ligands used in this area are the bidentate bicinchoninic acid (BCA) and 
bathocuproine disulfonate (BCS) (Figure 1.13) which both bind Cu1+ in a 1 : 2 complex with 
Cu1+ and display intense absorption in the visible region.  They have been proposed to 
buffer Cu1+ concentrations over the ranges 1012 – 1016 and 1015 – 1019 M-1 respectively,136 
making them ideal candidates for competing with higher-affinity proteins.  It is important to 
note that BCA has a lower Cu1+ affinity than BCS and for many of the highly selective copper 









Figure 1.13. Molecular structure of Cu1+-binding  ligands. Structures of  bathocuproinedisulfonic acid (BCS), bicinchoninic acid (BCA) and 


















1.13.4 Overall Formation Constants 
The competition method for calculation of a protein’s affinity for Cu1+ requires an accurate 
affinity value of the probe ligand against which the protein affinity can be measured.  In the 
case of the ligands L BCA/BCS which bind Cu1+ with a 2:1 stoichiometry, the affinity is defined 
as the overall formation constant β2 (Equation 1.3). 
𝐶𝑢+ + 2𝐿 ↔  𝐶𝑢+𝐿2 𝛽2 =  
[𝐶𝑢+𝐿2]
[𝐶𝑢+][𝐿]2
 Equation 1.3 
   
Unfortunately, the affinities of the probes have been disputed, and similarly to the affinities, 
a range of values have been reported in the literature (Table 1.2).   
Discrepancies are highly significant when these values are being used to calculate protein 
affinities, because reliable affinities are required in order to draw conclusions regarding the 
movement of copper.  For example, it has been suggested that copper is driven along 
particular routes due to affinity gradients,137 therefore an accurate set of affinities is 




Table 1.3. Literature values of formation constant (𝛽2 values) of BCA and BCS for Cu1+.  A 
























Considering that both BCS and BCA both bind Cu1+ in a 1 : 2 complex with Cu1+ and display 
intense absorption in the visible region, the simplest method for determining the formation 
constant would be a direct titration with Cu1+.  However, direct addition of Cu1+ results in 
quantitative binding and the amount of complex formation should not exceed 90 % at 
equimolar concentrations of metal ion to avoid large errors during data analysis.136  
One method for measuring the affinity of a ligand for a metal ion may be determined by 
potentiometric titration (Bjerrum titration) through competition with protons.  Ligands can 
be considered as Lewis bases since they donate electron pairs, and the pKa of a particular 
ligand atom at the site of copper binding is altered as the metal ion is bound.  The proton 
concentration can be accurately measured by a pH electrode, therefore reliable formation 
constants can be determined providing that the ligand pKa values are known.  This method 
has been used to measure the affinity of BCS, although due to the instability of Cu1+ in 
solution, the β2 of [Cu2+(BCS)2]2- was measured.  This was then used alongside the reduction 
potential of the Cu2+/Cu1+ couple and the Nernst equation to estimate the formation 
constant of [Cu1+(BCS)2]3-.138, 141  Unfortunately, uncertainties arise due to the ionic strength 
dependence of the reduction potentials and the structural differences between the mono- 
and divalent forms of the copper-BCS complexes.  Furthermore, it is difficult to apply this 
approach to [Cu2+(BCA)2]2- due to the similar pKa values of the carboxylate groups and the 
redox process of Cu2+/Cu1+ couple being irreversible which prevents the use of the Nernst 
equation. 
Alternative methods have utilised ITC  to measure the β2 of [CuI(BCA)2]2-,96 or competition 
with other known ligands or proteins. 138, 143, 144  This competition method has also been 
applied to BCS and a variety of ligands and proteins have been employed to provide affinity 
standards.19, 144  The use of cyanide as a competitive ligand has since been disapproved due 
to the presence of ternary complexes during the titration which prevent the derivation of a 








The primary hypothesis of the work presented here is that the mechanism of copper transfer 
between the yeast Ccs1 and its target, Sod1, is fundamentally different from that of the 
human system.  The foundation to the objectives used to test this hypothesis will be 
established via the expression of the full length wild-type Ccs1 protein and various Ccs1 
mutant proteins. Double Cys-to-Ser mutations of the copper-binding motifs in D1 and D3 of 
Ccs1 will allow individual copper-binding sites to be scrutinized whilst also minimising any 
changes to the overall structure of the protein. Truncated proteins containing either D1/2 or 
D2/3 only of Ccs1 will also allow individual binding sites to be studied, as well as establish 
any possible structural contributions of D1 or D3.  
The principal objectives to test this hypothesis are to determine the Cu1+ binding 
stoichiometries and affinity values for the copper binding motifs of D1 and D3 of Ccs1 using 
the Cu1+ ligands BCS and BCA. As these values have been determined for human CCS1, the 
measurement of these values in the yeast counterparts will enable a direct comparison. This 
will not only provide quantitative insight into the mechanism of copper transfer from Ccs1 to 
Sod1 in yeast, but also inform the proposed variation between the human and yeast copper-
transfer process as suggested in the literature.  
Another imperative objective is to investigate the activation of Sod1 by Ccs1 in vitro through 
the expression of Sod1 and the establishment of a Sod1 activity assay. This will identify the 
ability, if any, of the two distinct copper-binding sites of Ccs1 to activate Sod1 independently 
of each other and contribute to the overall discussion of the copper-transfer mechanism 
between Sod1 and Ccs1. 
A supplement to these objectives is to investigate the factors that affect the oligomeric 
status of Ccs1 and the mutant Ccs1 proteins.  This will allow direct comparison to the 
oligomeric status of the human CCS protein which has been extensively studied and 
designated as relevant to the mechanism of CCS function.  The potential factors affecting the 
oligomerisation of the Ccs1 proteins which are to be investigated include the presence or 
lack of Cu1+, loss of D1 or D3 and the disulphide status of the two copper binding sites.  
An associated hypothesis also investigated in this work is that Ccs1 and another copper 





for copper. This will be tested through determination of the affinity value for Axt1 using the 
same method as for Ccs1 and the Ccs1 mutants, which will provide a direct comparison 
between these proteins and acknowledge any potential interconnectivity between the Ccs1 
and Atx1 pathways. Specifically, this could inform whether Ccs1 and Atx1 could compete for 
copper from the same pool within the cell or identify a method for controlling copper 
distribution along particular pathways. This investigation will be supplemented via copper 
exchange experiments between Ccs1 and Atx1 to demonstrate whether the transfer of 
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2.1 Buffer solutions 
All buffer solutions were prepared using Milli-Q grade water (Millipore ‘Simplicity’ water 
purification system) with a rated resisitivity of ≥ 18M Ωcm.  For all solutions, the pH was 
adjusted by addition of either HCl (BDH, AnalR) or NaOH (Sigma).   
2.1.1 Tris(hydroxymethyl)aminomethane Buffer 
Tris(hydroxymethyl)aminoethane (Tris) (Sigma) buffer was used primarily in the pH range of 
7.0 to 7.5.  This buffer was mainly used for the isolation, purification and storage of proteins. 
2.1.2 Sodium Acetate Buffer 
Sodium acetate (NaOAc) (BDH) buffer was used to buffer solutions in the pH range 3.0 to 
6.0.  This buffer was primarily used for the dialysis procedure. 
2.1.3 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic Acid Buffer 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (Hepes) buffer was used to buffer 
solutions in the pH range 7.0 to 7.5.  This buffer was primarily used for copper binding 
experiments, exchange experiments and Sod1 activation experiments. 
2.1.4 2-(N-morpholino)ethanesulphonic Buffer 
2-(N-morpholino)ethanesulphonic (Mes) (Sigma) buffer was used to buffer solutions in the 
pH range 5.5-6.5.  This buffer was used primarily for protein purification. 
2.1.5 Phosphate buffer 
Phosphate buffer was primarily used for the Ellman’s thiol assay (Method 2.15).  Buffers 
were prepared by mixing stock solutions of 1 M dibasic and monobasic potassium 
phosphate, K2HPO4 and KH2PO4, respectively (Fluka).  Dibasic and monobasic phosphates 
were combined in the proportions shown in Table 2.1 for a particular pH.  Small adjustments 










K2HPO4 (mL) KH2PO4 (mL) pH 
13.2 86.8 6.0 
19.2 80.8 6.2 
27.8 72.2 6.4 
38.1 61.9 6.6 
49.7 50.3 6.8 
61.5 38.5 7.0 
71.7 28.3 7.2 
80.2 19.8 7.4 
86.6 13.4 7.6 
90.8 9.2 7.8 
94.0 6.0 8.0 
 
Table 2.1. Volumes of 1 M stocks of K2HPO4 and KH2PO4 required to prepare 1 L of 0.1 M 
potassium phosphate buffer solutions in the pH range 6.0 – 8.0. 
 
2.2 Measurement of pH values 
Measurement of pH values for buffer solutions were made using an Orion 420A pH meter 
connected to a Russell glass pH electrode (Thermo, type KCMAW11).  The pH meter was 
calibrated prior to use with two standard buffer solutions of either pH 4.0 and 7.0 or 7.0 and 
10.0 (Sigma) depending on the pH range measured. 
 
2.3 DNA Cloning 
2.3.1 Isolation of Plasmid DNA from Escherichia coli 
Plasmid DNA was isolated and purified from Escherichia coli (E. coli) using the GenElute 
Plasmid Miniprep Kit (Sigma).  A single colony of the fresh E. coli transformant containing the 
required plasmid were grown in 10 mL fresh LB with 100 μg/mL ampicillin or 100 μg/mL 
kanamycin, overnight at 37 °C and 250 rpm.  A 3-5 mL volume of the overnight culture was 
used to purify plasmid DNA. The purity of plasmid DNA was judged by measuring the UV 
spectrum and using the relative absorbances at 260 and 280 nm, where an A260/A280 ratio of 
1.5-1.8 usually indicated a suitably pure DNA sample with little RNA contamination. 
2.3.2 Determination of Plasmid DNA Concentration 
The concentration of plasmid DNA was determined by measuring the absorbance of a 





stranded DNA.  The concentration of primers purchased from Sigma was based on the DNA 
synthesis report provided by the companies. 
2.3.3 Plasmid DNA Digestion 
The digestion of plasmid DNA was carried out using restriction enzymes (BamH1 and Nde1, 
New England Biolabs) according to the manufacturer’s instructions to provide restriction 
sites for ligation reactions.  Typically ≈ 1000-3000 ng of plasmid DNA to be digested in a 50 
µL solution containing the required restriction enzymes was incubated at 37 oC for 2 hours 
followed by heating at 80 oC to inactivate the restriction enzymes. Digested plasmid was 
then loaded onto an agarose gel for DNA size determination and excision where required. 
2.3.4 Ligation Reactions of Plasmid and Insert DNA 
Ligation of digested plasmid DNA (pGEMT, Promega) and insert DNA was achieved using the 
T4 DNA ligase kit (Promega) according to the manufacturer’s instructions.  Required 
amounts of plasmid and insert DNA in 10 µL of T4 DNA ligase buffer with the appropriate 
amount of T4 DNA ligase were typically incubated at 4 °C overnight for ligation reaction. The 
ligation reaction sample was then transformed into fresh E. coli (JM101) competent cells. 
2.3.5 Gene amplification 
The polymerase chain reaction (PCR) was used to amplify the gene sequence for D1/2-Ccs1 
and D2/3-Ccs1 from pGEMT_WT_Ccs1 to incorporate Nde1/BamH1 restriction sites for 
ligation into pET29a vector.  The gene sequence for Sod1 was amplified from S. cerevisiae 
genomic DNA.  The PCR reaction contained 2 ng of template plasmid DNA, 0.4 mM 
deoxyribonucleotide triphosphates (dNTPs) mix (Promega), 125 ng of each primer (forward 
and reverse), 1 unit of Q5 polymerase (NEB) and 1 µL of 10x Q5 buffer made up to 10 µL. 
2.3.6 Cloning  
The plasmids pET29a_yCCS_WT, pET29a_yCCS_SC17-20S and pET29a_yCCS_SC229-231S 
were created previously by Stephen Allen and Adriana Badarau.  The DNA coding for 
residues 1-222 and 72 - 249 of Ccs1, corresponding to D1/2 and D2/3 respectively, were 
cloned (primers listed in Table 2.2) incorporating Nde1/BamH1 restriction sites and using the 
plasmid pGEMT_WT_Ccs1 to amplify the sequence.  The DNA coding for wild-type Sod1 
were cloned (primers listed in Table 2.2) incorporating Nde1/BamH1 restriction sites and 





into the Nde1 and EcoR1 restriction sites of pET29a giving pET29a_D1/2_Ccs1, 
pET29a_D2/3_Ccs1 and pET29a_ySod1 











Table 2.2. Primers used for making the D1/2-Ccs1 and D2/3-Ccs1 mutants, and cloning Sod1. 
2.3.7 DNA Sequencing 
DNA sequencing was used to verify truncated and amplified genes in plasmid DNA. Size and 
purity of DNA was typically assessed by agarose gel electrophoresis and measurement of 
absorbance of samples at 260 and 280 nm. DNA sequence analysis was then commissioned 
to Lark Technology (Beckman Coulter). 
 
2.4 Growing of E.coli 
All growth media was prepared in deionised water and sterilised by autoclaving at 121 oC for 
30 mins. 
2.4.1 Growth media LB 
Luria-Bertani (LB) medium consisted of 10 g/L tryptone (Melford), 10 g/l NaCl (Melford) and 
5 g/l yeast extract (Melford).  The LB-agar solid medium consisted of LB supplemented with 
15 g/l agar (Melford).  The medium was used to grow E. coli strains JM101 for molecular 
cloning and BL21 for protein expression, typically in the presence of the appropriate 
antibiotic (100 μg/mL ampicillin or 100 μg/mL kanamycin). 
2.4.2 Preparation of Competent E. coli cells 
LB was inoculated with a single colony of E. coli and incubated overnight at 37 oC with shaking 
(250 rpm).  The overnight culture was then diluted 100-fold into fresh LB (10ml) and grown for a 
further 2 hours under the same conditions. Cells were then spun down at 1500 × g for 10 mins 
and the cell pellet resuspended in ice cold TSS (1ml of a solution of 85% LB, 10% PEG, 5% DMSO 





2.4.3 Transformation of E. coli 
To 100 μL of competent cells 1-3 μL of plasmid DNA was added and incubated on ice for 20 
minutes before heat shocking at 42 oC for ≈ 1 min.  The solution was incubated on   
ice for a further 2 mins before adding 1 mL of LB and incubating at 37 oC with shaking 
(250rpm) for 1 hour.  After incubation, dilutions were made with LB and culture was plated 
onto freshly prepared LB-Agar plates with appropriate antibiotics (100μg/mL ampicillin or 
50μg/mL kanamycin). Plates were incubated overnight at 37 oC.145 
2.4.4 Expression studies: Total and Soluble Cell Protein 
In order to determine the growing period for optimal protein expression (as judged by SDS-
PAGE) small-scale trials were carried out with the pET29a expression plasmid, containing the 
required protein gene insert, transformed into E.coli strain BL21.  LB (10 ml containing 100 
μg/mL kanamycin for Ccs1 variants and Sod1) was inoculated with a single colony containing 
the expression plasmid and grown overnight at 37 oC with shaking (250 rpm). The next day a 
100-fold dilution of each culture into LB (50 ml containing 100 μg/mL kanamycin) was made 
and incubated for 2 hours at 37 oC with shaking (i.e. until the OD600 had reached ≈ 0.6-0.8). 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was then added to an effective concentration 
of 1 mM.  Samples (5 ml) of the cultures were taken at times of 0, 2, 4, 6 hours and overnight 
after induction with IPTG. The samples were spun down at 12,000 rpm in a desktop 
centrifuge for ≈ 5 mins, the supernatant removed and the cell pellet and resuspended in 
buffer.  Samples from cultures were sonicated and 100μl was removed for total protein 
content. The remaining solution was pelleted at ≈ 12,000 g in a desktop centrifuge for ≈ 5 
minutes and 100μl of the supernatant removed for soluble protein content.  Samples were 
then analysed by SDS-PAGE to judge an optimal cell harvesting time after protein induction. 
 
2.5 Overexpression and Purification of Proteins from E.coli BL21 
2.5.1 Overexpression of WT-Ccs1, the Cys-to-Ser mutants, D2/3-Ccs1, Atx1 and Sod1 
Escherichia coli BL21 transformed with either pET29a_yCCS_WT, pET29a_yCCS_SC17-20S, 
pET29a_yCCS_SC229-231S, pET29a_yD2_3_Ccs1, Atx1 and pET29a_ySod1 was grown in LB 
medium at 37 oC until an OD600 0.6 - 0.8 was reached.  Protein expression was induced by the 
addition of 1 mM Isopropyl β-D-thiogalactopyranoside, and cells were incubated for a 





2.5.2 Overexpression of D1/2-Ccs1 
Escherichia coli BL21 transformed with pET29a_yD1_2_Ccs1 were grown in LB medium at 37 
oC until an OD600 0.6 - 0.8 was reached.  Protein expression was induced by the addition of 1 
mM Isopropyl β-D-thiogalactopyranoside, and cells were incubated overnight at 16 oC before 
being harvested, with pellets stored at -30 oC. 
2.5.3 Purification of WT-Ccs1, Cys-to-Ser Mutants and Truncated Mutant D1/2-Ccs1 
Cells were resuspended in 20 mM tris(hydroxymethyl)aminomethane (Tris) pH 8.0, sonicated 
and centrifuged at 35,000 g for 20 min (+4oC). The supernatant was diluted 4-fold with Milli-
Q water prior to being loaded onto a self-packed DEAE-Sepharose column (50 mL, GE 
Healthcare). Protein was eluted with a linear NaCl gradient (0 – 500 mM) in 5 mM Tris (pH 
8.0).  Fractions containing Ccs1 [identified by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE)] were combined and exchanged via ultrafiltration (Amicon 
stirred cell with a 10 kDa molecular mass cutoff membrane) into 5 mM Mes (pH 6.5).  The 
final purification step included a HiTrap SP column (5 mL, GE Healthcare) with a 0 – 300 mM 
NaCl gradient, and fractions containing pure protein (≥ 90 % as judged by SDS-PAGE) were 
combined. 
2.5.4 Purification of Atx1 
Cells were resuspended in 20 mM tris(hydroxymethyl)aminomethane (Tris) pH 8.0, sonicated 
and centrifuged at 35,000 g for 20 min (+4 oC). The supernatant was diluted 4-fold with Milli-
Q water prior to being loaded onto a self-packed DEAE-Sepharose column (50 mL, GE 
Healthcare). Protein was eluted with cuts of buffer containing 0, 0.2, 0.4 and 1 M NaCl and 
fractions containing Atx1 were identified by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Protein fractions were combined and exchanged using 
ultrafiltration (Amicon stirred cell with a 5 kDa molecular mass cut-off membrane) into 10 
mM 2- (N-Morpholino) ethanesulfonic acid hydrate (Mes) pH 6.0.  The next purification step 
used a HiTrap SP column (5 mL, GE Healthcare) with a 0 – 300 mM NaCl gradient, and 
fractions containing Atx1 (as judged by SDS-PAGE) were combined and reduced to < 10 mL 
using ultrafiltration and 2 mM DTT added.  The final purification step used an S75 gel 
filtration column equilibrated with 20 mM Hepes, 200 mM NaCl ph 7.5 and injections 






2.5.5 Purification of Sod1 
Cells were resuspended in 20 mM tris(hydroxymethyl)aminomethane (Tris) pH 8.0, sonicated 
and centrifuged at 35,000 g for 20 min (+4oC). The supernatant was diluted 4-fold with Milli-
Q water prior to being loaded onto a self-packed DEAE-Sepharose column (50 mL, GE 
Healthcare). Protein was eluted with a linear NaCl gradient (0 – 500 mM) in 5 mM Tris (pH 
8.0).  Fractions containing Sod1 [identified by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE)] were combined and exchanged via ultrafiltration (Amicon 
stirred cell with a 10 kDa molecular mass cutoff membrane) into 5 mM Mes (pH 5.0).  The 
final purification step included a HiTrap SP column (5 mL, GE Healthcare) with a 0 – 300 mM 
NaCl gradient, and fractions containing pure protein (≥ 90 % as judged by SDS-PAGE) were 
combined. 
2.6 Ion exchange chromatography 
Ion-exchange chromatography was used for purification of proteins. Diethylaminoethyl 
(DEAE) sepharose (GE Healthcare) fast flow (FF) column material was used to prepare anion 
exchange columns for the purification of WT-Ccs1, C17S/C20S-Ccs1, C229S/C231S-Ccs1, 
D1/2-Ccs1, Atx1 and Sod1.  Hitrap SP (5 mL) columns (GE Healthcare) were used for 
purification of WT-Ccs1, C17S/C20S-Ccs1, C229S/C231S-Ccs1, D1/2-Ccs1 and Sod1.  HiTrap Q 
HP (1 mL) columns (GE Healthcare) were used for copper exchange experiments with Atx1. 
2.6.1 Equilibration of Ion-Exchange Column Material 
Ion-exchange column material (DEAE-Sepharose) was washed with 2 L of buffer solution 
prior to use of column for protein purification. The pH of the eluate was checked to ensure 
equilibration of column. All columns were ran and stored at 4 oC. 
2.6.2 Loading and elution of protein on Ion-Exchange Column Material 
Proteins were loaded onto DEAE sepharose column material in the same buffer as that of 
the column material. Elution of proteins was achieved by increasing the ionic strength of the 
buffer by providing a NaCl gradient between 0-500 mM NaCl by mixing two buffers with and 
without the salt. 
2.6.3 Regeneration of Ion-Exchange Column Material 
DEAE and SP sepharose FF column material was regenerated by washing with 500 ml of 2 M 





washed with 1 L of distilled water followed by 500 ml of 1 M NaOH (contact time ≈ 30 mins). 
The material was then washed with distilled water until the pH was neutral. Column 
materials were stored in 20 % ethanol at 4 oC. 
2.6.4 Ion-exchange using HiTrap Q Column 
Protein loading was achieved by syringe, and protein elution was achieved by applying buffer 
solutions with and without 200 mM NaCl through a peristaltic pump for separation of 
proteins in an anaerobic chamber for Cu1+ exchange experiments. 
2.7 Gel Filtration Chromatography 
Preparative gel filtration chromatography was used for the purification of proteins whilst 
analytical gel filtration chromatography was used to determine the oligomeric state of 
proteins. Masses of proteins, determined on preparative and analytical gel filtration 
chromatography columns, were deduced by comparison of elution volumes against a set of 
protein standards of known molecular weight (Method 2.7.2).   
2.7.1 Preparative Gel Filtration Chromatography 
A Supderdex 75 (10/300 GL GE Healthcare, 24 mL) column attached to an AKTA prime (GE 
Healthcare) was used for purification of proteins by gel filtration chromatography.  A buffer 
of 20 mM Tris pH 7.5 containing 200 mM NaCl was used as the column buffer.  Injection 
volumes were typically ≤ 2 % of the column volume and eluted at a flow rate of 1 mL/min.  
Elution of proteins was typically monitored at 280 nm and 215 nm (AKTA prime) or 280 nm 
(AKTA purifier).  
2.7.2 Analytical Gel Filtration Chromatography 
Analytical gel filtration chromatography was routinely performed on a Superex 75 column 
(10/300 GL GE Healthcare, 24 mL) column attached to an AKTA prime.  The column was 
equilibriated in 20 mm Hepes with 200 mM NaCl at pH 7.5 or 20 mm Hepes with 200 mM 
NaCl plus 250 µM DTT at pH 7.5 at a flow rate of 0.8 mL/min.  Absorbance was measured at 
280 nm and the typical injection volume of samples (10 – 200 µM) was 200 µL.  Buffer 
without DTT was routinely bubbled with nitrogen for 4 hrs and left in the anaerobic chamber 
overnight prior to use, and nitrogen was bubbled through during use.  The column was 
calibrated using a low molecular weight calibration kit (GE Healthcare) containing: blue 
dextran (2000 kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa), 






2.8.1 Centrifugal Ultrafiltration 
Amicon ultra 4 (10 kDa MWCO (molecular weight cut-off), Millipore) and Vivaspin 500 (5 kDa 
and 10 kDa MWCO, Sartorius) centrifugal concentrators were used to concentrate protein 
solutions and remove adventitiously bound metals through buffer exchange.  Exchanging 
buffer involved concentrating the protein solution and then diluting the sample 10-fold in 
the concentrator and repeating this process 3 times. A fixed angle rotor operating at ≈ 
12,000 g was used to centrifuge samples. 
2.8.2 Amicon Stirred Cell Ultrafiltration 
An Amicon stirred cell (200 mL cell, Amicon) fitted with an appropriate regenerated cellulose 
membrane (5-10 kDa MWCO, Millipore) was used to perform buffer exchanges during the 
purification of proteins.  A pressure of approximately 3-4 bar supplied from an N2 oxygen-
free cylinder was applied during operation of the stirred cell. 
 
2.9 Dialysis of protein solutions 
2.9.1 Preparation of dialysis tubing 
Dialysis tubing (14 kDa MWCO, Sigma) was prepared by soaking the tubing for 1 hour in an 
aqueous solution of 1 % acetic acid followed by exchange into distilled water and stirring for 
several minutes. The tubing was then placed into a solution of 1mM 
ethylenediaminetetraacetic acid (EDTA) and 1 % sodium carbonate and stirred for a further 
~3 minutes. The solution was then refreshed and the dialysis tubing heated to ~60 oC and 
then allowed to cool to room temperature over a period of 30 minutes. The above heating 
process was repeated once more and dialysis tubing exchanged into Milli-Q water and 
heated again to 60 oC and allowed to cool before storing in fresh Milli-Q water (at 4oC).(2) 
2.9.2 Dialysis of Sod1 Protein Solutions 
Dialysis was used for buffer exchange during the preparation of Zn-depleted WT-CCS. 
Dialysis tubing was washed thoroughly prior to use in buffer to be used during dialysis.  
Purified Sod1 was diluted four-fold with 50 mM sodium acetate at pH 3.8 and dialysed 
against 50 mM sodium acetate at pH 3.8 plus 10 mM EDTA at 4 oC with stirring for ≈ 5 hrs.  





refreshed again with the same buffer and stirred overnight.  The dialysis buffer was 
refreshed to 50 mM sodium acetate at pH 5.5 and stirred for a minimum of 3 hrs.  The buffer 
solution was typically 50-100 X sample volume. 
 
2.10 Electrophoresis 
2.10.1 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
A 12 % or 15 % acrylamide/bis-acrylamide (BioRAD) running gel containing 100 mM Tris pH 
8.8, 0.1 % SDS, 0.1 % ammonium persulfate (APS, Aldrich) and 0.05 % N,N,N’,N’-
tetramethylene diamine (TEMED, Aldrich) was prepared in deionised water and allowed to 
set for 30 mins.  The stacking gel, 5 % acrylamide/bis-acrylamide containing 100 mM Tris pH 
6.8, 0.1 % SDS, and 0.1 % APS and 0.1 % TEMED in deionised water, was poured directly on 
top of the running gel. A comb containing 10/15 ridges was inserted into the stacking gel to 
produce wells for sample loading. The stacking gel was allowed to set for 45 mins. Protein 
samples for electrophoresis were prepared in cracking buffer [50 mM Tris pH 6.8, 1 % SDS 
(Aldrich), 15 % glycerol (Sigma), 2 % DTT and 0.025 % bromophenol blue (BDH) in water. 
Protein samples in cracking buffer were heated at 95 oC for 5 mins. Typically 10 μL of this 
protein in cracking buffer was loaded into the wells of the gel. Broad range molecular weight 
marker (BioRAD) was loaded onto most gels as a reference. The SDS-PAGE buffer was 5 mM 
Tris pH 8.8 containing 200 mM glycine (Sigma) and 0.1 % SDS. All electrophoresis 
experiments were performed using a Mini-Protean II Cell from BioRAD with a constant 
voltage of 150-200 V applied from a powerpack.  
2.10.2 Non-Denaturing Polyacrylamide Gel Electrophoresis (NATIVE-PAGE) 
Gels prepared and ran as with SDS-PAGE gels (Method 2.10.1) without the use of SDS or a 
molecular weight marker. 
2.10.3 Agarose Gel Electrophoresis 
Agarose (0.8-1.5 %) (Melford) in electrophoresis buffer, Tris-acetate-EDTA (TAE: 40 mM Tris, 
40 mM acetate and 1mM EDTA pH 8.0) was heated in a microwave oven until all of the 
agarose dissolved. This was then cooled and poured into a tray with a comb with 8 or 15 
fingers. After ≈ 60 min the set agarose was transferred to an electrophoresis tank and 
covered with TAE buffer. DNA samples were mixed with 5X loading buffer and applied to a 





until the bromophenol blue approached the edge of the agarose gel. The Agarose gel was 
then stained by incubation in a solution of with GelRed Nucleic Acid Gel Stain (Biotium) 
diluted 10,000X in water for ≈ 20 mins. DNA in agarose gels was detected using an ultraviolet 
trans-illuminator (UV Tec). When DNA fragments in the agarose gel were required they were 
excised using a scalpel and purified from the agarose gel using the GeneElute Miniprep Kit 
(Sigma). 
 
2.11 Determination of the molecular weights of proteins 
Protein molecular weights were determined by either matrix assisted laser desorption 
ionisation time-of-flight (MALDI-TOF) or electrospray ionization mass spectrometry by Dr J. 
Gray (Pinnacle, Newcastle University, UK). 
 
2.12 UV/vis Spectroscopy 
All UV/Vis spectra were acquired on a Perkin-Elmer λ35 spectrophotometer. Measurements 
were made using 10 mm path length quartz cuvette (anaerobic cuvettes were used when 
anaerobic conditions required). 
 
2.13 Far-UV Circular Dichroism Spectroscopy 
Far-UV circular dichroism (CD) spectra (180-250 nm) of proteins were obtained on a Jasco J-
810 spectrometer using a 0.2 mm path length quartz cuvette. The cuvette compartment was 
maintained at a temperature of 20 oC during all measurements and 10 scans were 
accumulated per for both blank and protein sample spectra. 
 
2.14 Atomic Absorption Spectroscopy (AAS) 
Copper concentrations were determined by AAS using an M Series spectrometer (Thermo 
Electron Corp.) with a calibration range of 0.2 – 2 ppm copper in 2 % HNO3.  Protein samples 
were diluted to produce a concentration of copper at ≈ 1 ppm, assuming that the binding 
site(s) of the protein is saturated with copper (2 equivalents of copper for WT-Ccs1 and 
Sod1, 1 equivalent of copper for C17S/C20S-Ccs1, C229S/C231S-Ccs1, D1/2-Ccs1, Atx1).  A 





produce a concentration of zinc at ≈ 0.5 ppm, assuming that the binding sites of the proteins 
are saturated with zinc (2 equivalents of copper for WT-Ccs1 and Sod1, 1 equivalent of 
copper for C17S/C20S-Ccs1, C229S/C231S-Ccs1, D1/2-Ccs1, Atx1). 
 
2.15 Protein Reduction 
Protein samples (80 – 250 µM) were reduced by overnight incubation with 5 mM DTT at +4 
oC.  The samples were desalted and exchanged into the required buffer using a PD10 column 
(GE Healthcare) in an anaerobic chamber (Belle Technology, <2 ppm O2).  Protein reduction 
was confirmed by thiol quantification using 5,5 Dithiobis(2-nitrobenzoic acid) (DTNB, 
Ellman’s reagent).  The molar absorption coefficient ε = 14150 M-1 cm-1 was used for 
determining the number of free thiols per protein monomer.146 
 
2.16 Protein Quantification 
WT-Ccs1, C229S/C231S-Ccs1 and C17S/C20S-Ccs1 were quantified using the absorbance at 
280 nm and the calculated extinction coefficients (ε280) of 31315 M-1 cm-1 for WT-Ccs1 and 
31190 M-1 cm-1 for the mutants.  D1/2-Ccs1 was also quantified using the absorbance at 280 
nm and a ε280 of 25690 M-1 cm-1.  The ɛ280 for Sod1 (1615 M-1 cm-1) is too low to provide an 
accurate method of quantification from the absorbance at 280 nm.  Therefore 
concentrations determined from Bradford assays with D1/2-Ccs1 (quantified by absorbance 
at 280 nm) used for the standard curve provided protein concentrations. Concentrations of 
Atx1 were routinely quantified for reduced apo-protein using the Ellman’s assay and 
considering two cysteines. 
 
2.17 Spectroscopic Determination of Cu1+ Binding 
A Cu1+ stock solution (50 mM [Cu(CH3CN)4]PF6 in 100 % acetonitrile) was diluted 50-fold into 
the appropriate buffer and added to proteins using a gastight syringe (Hamilton).  Copper 
concentrations were determined using either bathocuproine disulphonate (BCS) or 
bicinchoninic acid (BCA).  For measurements using BCS and BCA, ε483 and ε562 values of 





2.17.1 Protein Cu1+ Binding Stoichiometries 
Cu1+ binding stoichiometries were determined by measuring the competition between 
proteins and BCA for Cu1+.  Titrations of Cu1+ into protein samples (10 µM) in the presence of 
150-500 µM BCA were performed with measurement of the increase in absorbance at 562 
nm due to the formation of [Cu(BCA)2]3-. Titrations were performed in 20 mM Hepes with 
200 mM NaCl at pH 7.5.  
2.17.3 Protein Cu1+ affinity determinations 
Protein Cu1+ affinities (Kb values) were determined by competition assays with BCS and BCA 
using an approach described previously.103, 139, 147  Titrations were performed by adding BCS 
(50 mM) or BCA (1 - 15 mM) into a solution of Cu1+-protein (10 µM) containing an excess of 
apo-protein (10 µM) with 0.5 equivalents of Cu1+ in all cases.  Apo-protein (500 – 1000 µM) 
was also titrated into a solution of [Cu(BCS)2]3- or [Cu(BCA)2]3- (10 µM) with an excess of BCS 
or BCA (50 – 700 µM).  After each addition of BCS/BCA or protein the absorbance at 483 or 
562 nm was measured, for determination of the concentrations of [Cu(BCS)2]3- or 
[Cu(BCA)2]3- respectively, after equilibration (typically 10-25 mins).  All titration data were fit 
using Origin 7 to a 1:1 Cu1+:protein binding model using equations (2.1) and (2.2) below. 
 
[𝐿] = 2[𝐶𝑢𝐿2] +  √
𝐾𝑏([𝑃] − [𝐶𝑢] + [𝐶𝑢𝐿2])[𝐶𝑢𝐿2]
([𝐶𝑢] − [𝐶𝑢𝐿2])𝛽
 Equation 2.1 
[𝑃] =  
([𝐶𝑢] − [𝐶𝑢𝐿2])([𝐿] − 2[𝐶𝑢𝐿2])
2𝛽
𝐾𝑏[𝐶𝑢𝐿2]
+ [𝐶𝑢 − [𝐶𝑢𝐿2] Equation 2.2 
 
In equations (2.1) and (2.2), [L] is the total concentration of BCS or BCA, [CuL2] is the 
concentration of [Cu(BCS)2]3- or [Cu(BCS)2]3-, [P] is the total protein concentration, [Cu] is 
total Cu1+ concentration, Kb is the proteins Cu1+ affinity constant and β is the overall affinity 
constant for formation of [Cu(BCS)2]3- or [Cu(BCA)2]3-.  [Cu(BCS)2]3- has an overall stability 
constant (βmax value) of 6.3 × 1019 M-2 (at pH ≥ 8.0),(12) and alterations in the βmax value with 






𝛽 =  
𝛽𝑚𝑎𝑥




2 Equation 2.3 
 
In which β is the overall affinity constant for [Cu(BCS)2]3- for a specified pH, βmax is the 
maximal overall stability constant of [Cu(BCS)2]3-, Ka is the acid dissociation constant of BCS 
and [H+] is the proton concentration. A β value for [Cu(BCA)2]3- of 5 x 1017 M-2 was used and a 
β value for [Cu(BCS)2]3- of 6.3 x 1020 M-2 was used at pH 7.5.  No significant difference was 
found at pH 7.0 and therefore the same β value has been used at these pH values. 
 
2.18 Cu1+ Exchange Experiments 
Cu1+ exchange between Atx1 and C17S/C20S-Ccs1 and C229S/C231S-Ccs1 was performed by 
mixing Cu1+-loaded protein with the partner apo-protein in 20 mM Hepes pH 7.5 (total 
volume 1 mL).  The mixtures were incubated for 1 – 24 hrs and loaded onto a HiTrap Q HP 
anion exchange column pre-equilibriated in the same buffer.  Atx1 did not bind to the 
column and was eluted with salt-free buffer (20 mM Hepes pH 7.5).  The Ccs1 mutants were 
eluted with 20 mM Hepes, 200 mM NaCl, pH 7.5 (1 mL fractions).  Protein concentrations in 
the fractions were determined using Bradford assays using D1/2-Ccs1 as the standard and 
Cu1+ concentrations were measured with BCS. The equilibrium concentrations were used for 
each set of partner proteins to calculate Kex from Equation 2. 
 









2.19 Activation of Sod1 by Ccs1 Variants 
The ability of Cu1+-loaded Ccs1 variants to activate E,Zn-Sod1 was assayed using a Sod1 nitro-





interaction with superoxide.  Superoxide ions are produced photochemically by the 
reduction of riboflavin.  Sod1 catalyses the dismutation of superoxide therefore the 
presence of achromatic zones on an otherwise purple/blue gel is a reduction in the 
appearance of NBT-diformazan and a measure of Sod1 activity present in the sample.  
Reaction mixtures typically consisted of 5 µM E,Zn-Sod1, 5 µM Cu1+-Ccs1, 100 µM EDTA and 
100 µM BCS.  E,Zn-Sod1 and Cu,Zn-Sod1 was prepared by the addition of equal quantities of 
E,E-Sod1, ZnSO4 and/or Cu2+(NO3)2.  Cu1+-Ccs1 proteins were incubated for 30 mins prior to 
being mixed with E,Zn-Sod1, EDTA and BCS.  Once combined, samples were exposed to air, 
incubated at 37 oC for 1 hr and loaded onto a NATIVE-PAGE gel.  Gels were stained with a 
solution containing 100 mM sodium phosphate at pH 7.0, 4.3 % N,N,N’,N’-
tetramethylethylenediamine and 2.8 mM µM riboflavin for 20 mins with shaking.  Exposure 
of the gel to bright light for 5 mins initiated the formation of superoxide and the gel 
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3.1 Purification and Initial Characterisation of Proteins 
All of the proteins expressed and purified in this project were determined by SDS-PAGE to be 
> 90 % pure. The molecular weights of WT-Ccs1, C17S/C20S-Ccs1, C229S/C231S-Ccs1, D1/2-
Ccs1 and Sod1 were determined to be within 7 Da of expected values (Table 3.1).  All of the 
proteins are mixtures of protein comprised of the full amino acid sequence or lacking the N-
terminal methionine due to removal of the N-terminal methionine by methionine 
aminopeptidase (MetAP).148  However, Sod1 was measured only as protein lacking the N-
terminal methionine, both with and without a water adduct, and a peak with a mass 117 Da 
less than the expected value was present.  Furthermore, D2/3-Ccs1 has a mass 191 Da less 
than expected value (60 Da less than expected for protein lacking N-terminal methionine) 
and appeared as a mixture of monomer and dimer.  These discrepancies in the measured 
masses of the D2/3-Ccs1 and Sod1 proteins are not easily explained.  All Ccs1 variants and 
Atx1 were purified with negligible amounts of copper and zinc.  Sod1 was purified with 
negligible amounts of copper and ≈ 0.7 zinc equivalents per protein monomer. 
Reduced apo-protein samples provided the numbers of free thiols per monomer, 
determined using the Ellman’s assay (Method 2.15) and protein concentrations. The 
concentration of proteins were determined using the absorbance at 280 nm and calculated 
ɛ280 values (Methods 2.16) from the online ExPASy ProtParam tool.1  Values of 4.7 ± 0.4, 2.7 ± 
0.5 and 3.0 ± 0.5 (n = 10) thiols per monomer were obtained for apo-WT-Ccs1, C17S/C20S-
Ccs1 and C229S/C231S-Ccs1 (Table 3.2).  The D1/2-Ccs1 mutant which lacks D3, gave 2.9 ± 
0.1 (n = 10) thiols per monomer (Table 3.2).  WT-Ccs1 contains 7 cysteine residues therefore 
the expected thiol count is 7, the C17S/C20S-Ccs1, C229S/231S-Ccs1 and D1/2-Ccs1 variants 
contain 5 cysteine residues therefore the expected thiol is 5.  The calculated ɛ280 of Sod1 
(1615 M-1 cm-1) is too low to provide an accurate method of quantification from the 
absorbance at 280 nm.  Therefore concentrations determined from Bradford assays with 
D1/2-Ccs1 (quantified by absorbance at 280 nm) were used for the standard curve provided 
protein concentrations.  A comparison to the thiol concentration determined using the 
Ellman’s assay gave 1.8 ± 0.2 (n = 10) thiols per monomer (Table 3.2).   
 Concentrations of Atx1 determined from the absorbance at 280 nm and the calculated ɛ280 
of 4470 M-1 cm-1 gave values ≈ 200 % higher than those from the Ellman’s assay.  Also, the 





concentrations of Atx1 were routinely quantified for reduced apo-protein using the Ellman’s 
assay (Method 2.15) and considering two cysteines.   
 
3.2 Far-UV Circular Dichroism (CD) Spectra 
CD spectroscopy is a form of light absorption spectroscopy that measures the difference in 
absorbance of right- and left-handed polarized light by a substance. It has been shown that 
CD spectra between 260 - 180 nm can be analyzed for the different secondary structural 
content such as alpha helices, parallel and antiparallel beta sheets.2, 149  
CD spectroscopy was performed on WT-Ccs1 and the Ccs1 variants in order to determine if 
the Cys-to-Ser mutations of C17S/C20S-Ccs1 and C229S/C231S-Ccs1, or loss of domain in 
D1/2-Ccs1 and D2/3-Ccs1 caused any structural disruption.  Far-UV CD spectra show that the 
Cys-to-Ser mutations in C17S/C20S-Ccs1 and C229S/C231S-Ccs1, as well as the loss of D3 in 
D1/2-Ccs1 do not alter the overall secondary structure relative to WT-Ccs1 (Figure 3.1).  All 
Ccs1 spectra contain a main positive peak at ≈ 187 nm which is indicative of α-helical 
content, and a minor positive peak at ≈ 200 nm which is indicative of β-sheet content, which 
correspond to the spectrum previously reported for Ccs1.103  In contrast, the CD spectrum 
for the D2/3-Ccs1 mutant, which lacks D1, contains a large negative peak at 195 nm 
indicating that the protein is significantly unfolded, existing mainly as a an irregular 
structure.150  The similarities of CD spectra between unfolded polypeptides and those 
containing polyproline II (PPII) helix-like confirmations, which are characterised by a distinct 
negative peak at < 200, have suggested that Iirregular structures may actually have some 
organisational structure such as PPII confirmations.36 Due to this dramatic loss of secondary 
structure as compared to WT-Ccs1, the D2/3-Ccs1 protein was therefore not used for any 
further experiments.  
Subtraction of the far-UV CD spectrum of D1/2-Ccs1 from that of WT-Ccs1 provides a 
spectrum for D3-Ccs1 (Figure 3.2).   The presence of a negative peak at 200 nm is 
characteristic of small unstructured peptides.151   
The Far-UV CD spectrum of Atx1 partly resembles that of WT-Ccs1 due to a positive peak at 
≈ 190 nm, however the minor positive peak at ≈ 200 nm of the Ccs1 proteins is lacking in the 





210 nm which is identical to that measured previously for Atx1 of S. cerevisiae.140  In the 
literature, two negative peaks at ≈ 108 and 220 nm characteristic of α-helical content are 
observed for Atx1 of S. cerevisiae,7 and the cyanobacterium Synechocystis.140, 147   
The secondary structure of Sod1 was monitored at each stage of a dialysis procedure 
(Method 2.9.2) for zinc removal from the purified E,Zn-Sod1 (Results 3.1).  The copper and 
zinc content of Sod1 was measured by Atomic Absorption Spectroscopy (AAS) at each stage 
of the dialysis procedure.  After incubation at pH 3.8 and treatment with EDTA, which 
removes zinc to form E,E-Sod1 undergoes significant unfolding indicated by a large negative 
peak at 200 nm (Figure 3.4).  Transfer to pH 5.5 shows that E,E-Sod1, begins to refold and 
regain some secondary structure, indicated by the small positive peak at 195 nm.  Incubation 
of E,E-Sod1 at pH 7.5 shows further secondary structure organisation, however, the 
complete folded protein form is only achieved upon the addition of zinc.  Further addition of 
copper to E,Zn-Sod1 does not affect the overall structure (Figure 3.4). 
 
3.3 Analytical Gel Filtration Chromatography 
Analytical gel filtration chromatography was used to determine the oligomeric state of Ccs1 
in the apo-form and when Cu+ is bound (Method 2.7.2).   
In the absence of Cu1+, WT-Ccs1, C229S/C231S-Ccs1 and D1/2-Ccs1 are predominately 
monomeric (Figure 3.5 A, B & C) with a small proportion of dimer (11, 4, 3 % dimer 
respectively).  C17S/C20S-Ccs1 is shown to form equal proportions of monomer and dimer 
indicating that this mutant is more readily prone to dimerization (Figure 3.5 D) than WT-Ccs1 
and the other Ccs1 mutants.  The presence of DTT in the buffer reduces the amount of dimer 
present with WT-Ccs1 and C17S/C231S-Ccs1 (from 11 to 8 % and 3 to 2 peak shift % dimer 
respectively), and eliminates dimer formation in C229S/C231S-Ccs1 and D1/2-Ccs1.  This 
shift in monomer : dimer ratio in the presence of the reducing agent DTT indicates that 
dimerization is most probably due to inter-molecular disulfide bonds.   
Upon the binding of Cu1+, both dimeric and monomeric species of WT-Ccs1 are observed 
(Figure 3.6 A) which persist in the presence of DTT (Figure 3.6 B).  The occurrence of 
dimerization in the presence of a reducing agent and increasing dimer formation observed 





and not disulfide formation.  Dimerization upon the addition of Cu1+ is also observed for 
C229S/C231S-Ccs1 and D1/2-Ccs1 (Figure 3.7 A & C). The presence of dimer increases with 
Cu1+ concentration from 4 % for apo-C229S/C231S-Ccs1 to 16 and 34 % for 0.5 and 1.0 
equivalents of Cu1+ bound respectively.  The presence of dimer increases with Cu1+ 
concentration from 4 % for apo-D1/2-Ccs1 to 13 and 33 % for 0.5 and 1.0 equivalents of Cu1+ 
bound respectively.  However, this dimerization is eliminated in the presence of DTT (Figure 
3.7 B & D).  C17S/C20S-Ccs1 shows the highest proportion of dimer formed with the addition 
of copper (Figure 3.7 E), increasing from 49 % for apo-C17S/C20S-Ccs1 to 61 and 77 % for 0.5 
and 1.0 equivalents of Cu1+ bound respectively.  Dimer formation is reduced in the presence 
of DTT (Figure 3.7 F), yet the dimer remains a major form in presence of DTT (5 % for apo-
C17S/C20S-Ccs1 to 49 and 59 % for 0.5 and 1.0 equivalents of Cu1+ bound respectively) 
suggesting that dimerization is not disulfide linked and is related to the binding of Cu1+. 
Copper is found to associate with both the monomeric and dimeric forms of WT-Ccs1 (Figure 
3.8).  At 0.5 and 1.0 equivalents of Cu1+, the copper is found to associate almost equally 
between the monomeric and dimeric protein forms (Figure 3.8 A & B).  At Cu1+ 
concentrations over 1.0 equivalent, copper is found to preferentially bind to the monomer 
(Figure 3.8 C & D).  In the presence of DTT the resolution of the peaks is diminished, 
although Cu1+ appears to preferentially bind to the dimeric protein up to 1.0 equivalent of 
copper (Figure 3.9 A & B).  At higher Cu1+ concentrations it is not possible to distinguish 
monomer/dimer peaks (Figure 3.9 C & D). 
Copper also binds to both the monomer and dimer of C229S/C231S-Ccs1 (Figure 3.10 A & B). 
In the presence of DTT only monomeric protein is present therefore Cu1+ is only found to 
associate with the monomer (Figure 3.10 C & D).  Copper association with D1/2-Ccs1 is 
identical to C229S/C231S-Ccs1, (Figure 3.11).  The corresponding Cu1+ binding 
oligomerisation of C229S/C231S-Ccs1 and D1/2-Ccs1 is expected since both proteins only 
contain the copper binding site in D1 of Ccs1. 
The addition of Cu1+ to C17S/C20S-Ccs1 shows that Cu1+ favours association with the dimeric 
protein (Figure 3.12 A & B), which could be due to preferential binding interactions or the 
higher majority of dimer present over monomer.  Interestingly, in the presence of DTT at the 





(Figure 3.12 C).  At the Cu1+ concentration of 1.0 equivalent the protein peaks are not 
resolved therefore the exact location of Cu1+ cannot be distinguished (Figure 3.12 D).  
Analytical gel filtration chromatography was also used to determine the oligomeric form of 
apo-Atx1 and the Cu1+-bound form.   In the absence of Cu1+, 67 % of apo-Atx1 is dimeric in 
the absence of DTT and 59 % is dimeric in the presence of DTT (Figure 3.13).  Upon the 
addition of Cu1+ the monomer : dimer ratio shifts to favour the monomer and Cu1+ is found 
to be associated with the monomer (Figure 3.14).  Previously, the major form of Atx1 was 
found to be the  monomer regardless of the presence or absence of copper.31  
Purified Sod1 was shown by analytical gel filtration to be dimeric in the presence of DTT 
(Figure 3.15), and monomeric protein was only observed after incubation of Sod1 with DTT 
overnight.80, 152, 153  
 
3.4 Cu1+ Binding Stoichiometries of Ccs1 variants 
Cu1+ binding stoichiometries were determined by titrating Cu1+ into apo-protein in the 
presence of BCA (Method 2.17.1).  C229S/C231S-Ccs1 and D1/2-Ccs1 bind ≈ 1 equivalent of 
Cu1+ in the presence of 500 µM BCA (Figure 3.16 B & D), whereas WT-Ccs1 is shown to bind 
beyond one equivalent of Cu1+ due to weak competition with BCA (Figure 3.16 A).  Similarly, 
C17S/C20S-Ccs1 shows weak competition with BCA, therefore the binding stoichiometry 
cannot be determined (Figure 3.16 C).  Reduction of the BCA concentration to 150 µM shows 
that WT-Ccs1 is able to bind two equivalents of Cu1+, and C17S/C20S-Ccs1 binds one 
equivalent of Cu1+ (Figure 3.17).  WT-Ccs1 and the Ccs1 mutants show identical Cu1+ binding 
stoichiometry as the human homologues.103 
 
3.5 Cu1+ Binding Affinities of Ccs1 variants 
The Kb values of the two Cu1+ binding sites of Ccs1, located in D1 and D3, have been 
measured individually by competition titrations with Ccs1 mutants containing only one of 
the two copper-binding sites of Ccs1 and BCS/BCA (Method 2.17.3).  Since WT-Ccs1 contains 
two copper-binding sites, 0.5 equivalents of Cu1+ was used in all affinity titrations.  The Cu1+ 
affinity of WT-Ccs1, C229S/C231S-Ccs1 and D1/2-Ccs1 for Cu1+ have been measured as 





(Figure 3.18 and Table 3.4).  The agreement between the affinity of WT-Ccs1 and those of 
the Ccs1 variants containing the copper-binding site of D1 only indicates that the 0.5 
equivalent of Cu1+ used in the affinity titrations was bound to D1 of WT-Ccs1.  Titrations of 
apo-protein into [Cu(BCS)2]3- provided comparable values which confirm that equilibrium 
conditions  were reached in the experiments and therefore validate the determined values 
and the methods used (Figure 3.19). 
The addition of a relatively low concentration of BCS to Cu1+-C17S/C20S-Ccs1 resulted in the 
removal of ≈ 70 % Cu1+ by BCA over the course of 5 hours (Figure 3.20).  As suggested from 
the stoichiometry titrations, this removal of Cu1+ suggests a lower affinity of the D3 copper-
binding site for Cu1+.  Therefore, experiments with BCA were performed to measure the Cu1+ 
affinity of C17S/C20S-Ccs1 as done previously with the equivalent human CCS1 mutant 
(Method 2.17.3).103  Experiments performed under the previous conditions involved the 
incubation of several samples of C17S/C20S-Ccs1 plus 0.5 equivalents of Cu1+ with a range of 
BCA concentrations for a period of 48 hrs.  This resulted in plots (Figure 3.21 A) which lacked 
the typical trend of the affinity plots for WT-Ccs1 and C229S/C231S-Ccs1, and the Cu1+ 
affinity measured is an order of magnitude higher than that measured by titrations of apo-
C17S/C20S-Ccs1 into [Cu(BCA)2]3- (Figure 3.21 B).  The extension of the affinity experiments 
after the experimental time frame of 48 hrs showed the prolonged and eventual complete 
removal of Cu1+ from C17S/C20S-Ccs1 by BCA (Figure 3.22).  This renders the Cu1+ affinity 
values obtained by these conditions as invalid.  Monitoring of the free thiol count of 
C17S/C20S-Ccs1 over time in the presence of Cu1+ and BCA shows that these components do 
not affect the oxidation state of the cysteine residues, therefore the prolonged loss of Cu1+ is 
not due to oxidation of the protein.  Similarly, monitoring of the thiol state of WT-Ccs1 
shows that the presence of BCA does not cause oxidation of the cysteine residues (Figure 
3.23).  In order to check the stability of WT-Ccs1 during the affinity experiments, several 
points of the titration were monitored over time and remained stable, showing that Cu1+ 
removal by BCS was completed within the time frame of each titration addition (≈ 15 min) 
(Figure 3.24).   
The continuation of Cu1+ removal from C17S/C20S-Ccs1 by BCA outside of the experimental 
time frame suggested that this may also occur in experiments consisting of titrating apo-





that Cu1+ removal from [Cu(BCA)2]3- by C17S/C20S-Ccs1 occurred within the time frame of 
each titration addition (≈ 15 min) and remained stable (Figure 3.25).  This method and 
conditions were therefore approved to measure the affinity value of C17S/C20S-Ccs1 for 
Cu1+, and the Kb value has been measured as (4.1 ± 0.9) x 1017 M-1 which is less than three 
times lower than WT-Ccs1 (Figure 3.21 B and Table 3.4). 
 
3.6 Cu1+ Binding Affinities of Atx1 
The Kb value for Cu1+ binding to Atx1 were determined from competition titrations with BCS 
at pH 7.0 and 7.5 (Method 2.18).  Measurement of the Cu1+ affinity at pH 7.5 allows a direct 
comparison to the Ccs1 affinities measured here, whereas an affinity at pH 7.0 can be used 
to compare with previous literature values.139  The affinity of Cu1+ binding to Atx1 measured 
by titration of BCS into Cu1+-Atx1 at pH 7.0 is (4.2 ± 1.4) x 1018 M-1 (Figure 3.26 A and Table 
3.4).  This is consistent with measurements provided by titrations of apo-Atx1 into 
[Cu(BCS)2]3- (Figure 3.26 B) which indicate that equilibrium has been reached and therefore 
validate the determined values and the methods used.  Experiments performed at pH 7.5 
provided a Kb value greater than three times higher than the value at pH 7.0, and also 
provide consistent measurements from titrations of BCS into Cu1+-Atx1 and apo-Atx1 into 
[Cu(BCS)2]3- (Figure 3.26 and Table 3.4).  
 
3.7 Cu1+ Transfer between Atx1 and Ccs1 variants 
Copper transfer between Atx1 and either C17S/C20S-Ccs1 or C229S/C231S-Ccs1 at pH 7.5 
was performed with Cu1+-loaded Atx1 with an apo-Ccs1 variant, and apo-Atx1 with a Cu1+-
loaded Ccs1 variant.  The Kex values were determined and compared to the Ktheo values 
calculated from the Cu1+ affinities measured (Method 2.18).  Atx1 and Ccs1 were separated 
using an anionic Hitrap Q column at pH 7.5.  Atx1 did not bind whereas the Ccs1 proteins 
were eluted with buffer plus 200 mM NaCl (Figure 3.28).   
The transfer of Cu1+ between Atx1 and C229S/C231S-Ccs1, in both experiments where Cu1+ 
originated with one of the partner proteins, was found to be complete within the timeframe 





which is due to a difference in the equivalent equilibrium protein concentrations by only 1 
µM.   
The Cu1+-transfer between Atx1 and C17S/C20S-Ccs1 within the same timeframe (≈ 1 hr) 
provided Kex values which are not consistent (Table 3.6) due to differences of the equivalent 
equilibrium protein concentrations which signifies that equilibrium was not reached.  A 
significantly longer incubation period (≈ 24 hr) provided identical equivalent equilibrium 
protein concentrations and Kex values which demonstrates that equilibrium was achieved, 
and shows that the reaction with C17S/C20S-Ccs1 is slower but completed within the 
allotted timeframe (Table 3.7).  The Kex values show a similar trend to the calculated Ktheo 
values (Table 3.6) indicating that a greater level of exchange is possible between 
C229S/C231S-Ccs1 and Atx1 than C17S/C20S-Ccs1 and Atx1. 
 
3.8 Activation of Sod1 by Ccs1 
The activity of Sod1 was determined by the proteins ability to catalyse the dismutation of 
superoxide and visualised by means of an NBT assay (Method 2.19) in which the formation of 
NBT-diformazan by superoxide is diminished by the presence of catalytically active Cu,Zn-
Sod1.  The dismutation of superoxide by Cu,Zn-Sod1 causes achromatic areas at its location 
on an otherwise purple/blue gel.   
Cu,Zn-Sod1 formed from incubation with the salts ZnSO4 and Cu2+(NO3)2 was shown to be 
enzymatically active using the NBT assay (Method 2.19) and yeast Sod1 was shown to run at 
a similar level to bovine erythrocyte SOD1 by native-PAGE (Figure 3.30).  These experiments 
were performed aerobically with E,E-Sod1 which was not reduced therefore the catalytically 
important disulphide bond remained intact.  Furthermore, no activity was observed with 
E,Zn-Sod1.  Achromatic bands on the native-PAGE gels indicating activity of Sod1 were 
observed to be very intense at relatively low concentrations of protein therefore the 
optimum concentration of Sod1 to be loaded onto native-PAGE gels for the NBT assay was 
determined as 100 ng (Figure 3.29).   
None of the isolated Cu1+-Ccs1 variants show achromatic bands in the NBT assay compared 
to Cu,Zn-Sod1 (Figure 3.31) at the same concentration of 100 ng.  Sod1 activity is observed 





activation similar to that observed from E,Zn-Sod1 plus Cu2+(NO3)2.  All of the Ccs1 variants 
(C17S/C20S-Ccs1, C229S/C231S-Ccs1 and D1/2-Ccs1) provide lower activity levels of Sod1 
compared to WT-Ccs1.  However, the activity of Sod1 observed after incubation with Cu1+-
C17S/C20S-Ccs1 is higher than with the Ccs1 variants which contain the D1 copper-binding 
site only (C229S/C231S-Ccs1 and D1/2-Ccs1).  Comparison of the Sod1 activity produced 
after incubation with Cu1+-WT-Ccs1 and Cu1+-C17S/C20S-Ccs1 over a range of decreasing 
concentrations (Figure 3.33) definitively shows that WT-Ccs1 produces a greater level of 
activation than C17S/C20S-Ccs1.  Sod1 activity is equally lower after incubation with Cu1+-


































































































a Matrix assisted laser desorption/ionization mass spectrometry  
b Values for proteins without the N-terminal methionine  
c Difference values calculated from [experimental mass – theoretical mass] 






















Table 3.2. Experimental and expected free thiol count for Ccs1 proteins and Sod1 as determined by 
the Ellman’s assay. 
 
Protein 
Experimental free  
thiol counta 
Expected free  
thiol countb 
WT-Ccs1 4.7 ± 0.4 7 
C17S/C20S-Ccs1 2.7 ± 0.5 5 
C229S/C231S-Ccs1 3.0 ± 0.5 5 
D1/2-Ccs1 2.9 ± 0.2 5 
Sod1 1.8 ± 0.2 2 
 
a Calculated from the Ellman’s assay and protein concentration (Methods 2.15) and Average values 
from ten independent determinations. 


















Figure 3.1. Far-UV CD spectra of WT-Ccs1 and Cys-to-Ser apo-Ccs1 variants indicating the 
secondary structure of the proteins. Apo-WT-Ccs1 (black), apo-C17S/C20S-Ccs1 (red), apo-
C229S/C231S-Ccs1 (green), apo-D1/2-Ccs1 (blue) and apo-D2/3-Ccs1 (orange) in 100 mM 
potassium phosphate at pH 8.0, and protein concentrations 0.50 mg/mL, 20oC. The D2/3-


















Figure 3.2. The calculated far-UV CD spectrum of D3-Ccs1 protein. This spectrum of D3-Ccs1 
was calculated by subtracting the spectrum of D1/2-Ccs1 from that of WT-Ccs1 (both shown 
in Figure 3.1). This resulting spectrum resembles that for an unstructured peptide 




















Figure 3.3. Far-UV CD spectrum of apo-Atx1 indicating the secondary structure of the 
protein. The data was obtained on an apo-Atx1 sample (0.50 mg/mL) in 100 mM potassium 






















Figure 3.4. Far-UV CD spectra of Sod1 after purification and at various stages of the dialysis 
protocol to remove zinc. Purified E,Zn-Sod1 [binding 0.7 equivalents of Zn2+] at pH 7.5 
(black), E,E-Sod1 at pH 3.8 (red), E,E-Sod1 at pH 5.5 (green), E,E-Sod1 at pH 7.5 (navy), E,Zn-
Sod1 [plus 1.0 equivalent of Zn2+] at pH 7.5 (cyan) and Cu,Zn-Sod1 [plus 1.0 equivalent of 
Cu2+ and Zn2+] at pH 7.5 (magenta). All protein concentrations were 0.50 mg/mL and spectra 
were measured at 20oC. Sod1 without Zn2+ bound becomes unfolded at pH 3.8 and refolds 

















Table 3.3. Gel filtration elution volumes and apparent molecular weights of apo and Cu1+-
bound WT and mutant Ccs1 proteins under anaerobic and aerobic conditions 
 
Proteina 













































































































a Gel filtration performed at room temperature on a Superdex 75 10/300 GL column either under 
aerobic conditions using 20 mM Hepes at pH 7.5 plus 200 mM NaCl with 250 µM DTT or 
anaerobically using deoxygenated 20 mM Hepes at pH 7.5 plus 200 mM NaCl. 
b Apparent masses were calculated from elution volumes and a column calibration performed with a 
low molecular weight calibration kit (Methods 2.7.2) and indicate the presence of monomeric and/or 




















Figure 3.5. Gel filtration chromatograms of WT and mutant apo-Ccs1 proteins either under 
anaerobic conditions or in the presence of DTT. Plots of absorbance at 280 nm against 
elution volume for (A) apo-WT-Ccs1, (B) apo-C229S/C231S-Ccs1, (C) apo-D1/2-Ccs1 and (D) 
apo-C17S/C20S-Ccs1 in deoxygenated 20 mM Hepes at pH 7.5 plus 200 mM NaCl (black) or 
20 mM Hepes at pH 7.5 plus 200 mM NaCl with 250 µM DTT (blue). Proteins (100 µM of 200 
µL) were injected onto a Superdex 75 10/300 GL column at a flow rate of 0.8 mL/min at 


















Figure 3.6. Gel filtration chromatograms of WT-Ccs1 protein with various equivalents of Cu1+ 
bound either under anaerobic conditions or in the presence of DTT. Plots of absorbance at 
280 nm against elution volume for apo-WT-Ccs1 (black) and WT-Ccs1 in the presence of 0.5 
equivalents Cu1+ (red), 1.0 equivalent Cu1+ (green), 1.5 equivalents Cu1+ (navy) and 2.0 
equivalents Cu1+ (cyan) in (A) deoxygenated 20 mM Hepes pH 7.5 plus 200 mM NaCl or (B) 
20 mM Hepes pH 7.5 plus 200 mM NaCl and 250 µM DTT. Proteins (100 µM of 200 µL) were 
injected onto a Superdex 75 10/300 GL column at a flow rate of 0.8 mL/min at room 
































Figure 3.7. Gel filtration chromatograms of apo- and Cu1+-bound Ccs1 variants either under 
anaerobic conditions or in the presence of DTT. Plots of absorbance at 280 nm against 
elution volume for C229S/C231-Ccs1 (A and B), D1/2-Ccs1 (C and D) and C17S/C229S-Ccs1 (E 
and F) as apo-protein (black) and in the presence of 0.5 Cu1+ (red) and 1.0 equivalent Cu1+ 
(blue) in deoxygenated 20 mM Hepes pH 7.5 plus 200 mM NaCl (A, C and E), or 20 mM 
Hepes pH 7.5 plus 200 mM NaCl and 250 µM DTT (B, D and F). Proteins (100 µM of 200 µL) 
were injected onto a Superdex 75 10/300 GL column at a flow rate of 0.8 mL/min at room 
















Figure 3.8. Distribution of WT-Ccs1 and Cu1+ in eluted fractions from a gel filtration column. 
Protein (●) and Cu1+ (○) content of fractions (500 µL) for WT-Ccs1 in the presence of (A) 0.5, 
(B) 1.0, (C) 1.5 and (D) 2.0 equivalents of Cu1+ in deoxygenated 20 mM Hepes pH 7.5 plus 200 
mM NaCl. Proteins (100 µM of 200 µL) were injected onto a Superdex 75 10/300 GL column 
and eluted at a flow rate of 0.8 mL/min at room temperature. For elution volumes and 
calculated apparent molecular weights see Table 3.3. Cu1+ is associated with both 






















Figure 3.9. Distribution of WT-Ccs1 and Cu1+ in eluted fractions from a gel filtration column. 
Protein (●) and Cu1+ (○) content of fractions (500 µL) for WT-Ccs1 in the presence of (A) 0.5, 
(B) 1.0, (C) 1.5 and (D) 2.0 equivalents of Cu1+ in 20 mM Hepes pH 7.5 plus 200 mM NaCl with 
µM DTT. Proteins (100 µM of 200 µL) were injected onto a Superdex 75 10/300 GL column 
and eluted at a flow rate of 0.8 mL/min at room temperature. For elution volumes and 
calculated apparent molecular weights see Table 3.3. Cu1+ is associated with both 






















Figure 3.10. Distribution of C229/C231S-Ccs1 and Cu1+ concentrations in eluted fractions 
from a gel filtration column performed in deoxygenated buffer or the presence of DTT. This 
shows the oligomeric form and location of Cu1+. Only monomeric C229S/C231S-Ccs1 is 
shown to be present in the presence of DTT . Protein (●) and Cu1+ (○) content of gel filtration 
fractions of C229S/C231S-Ccs1 in the presence of  0.5 (A and C) and 1.0 (B and D) equivalents 
Cu1+ in deoxygenated 20 mM Hepes pH 7.5 plus 200 mM NaCl (A and B) and the same buffer 
plus 250 µM DTT (C and D). Proteins (100 µM of 200 µL) were injected onto a Superdex 75 
10/300 GL column and eluted at a flow rate of 0.8 mL/min at room temperature. For elution 
volumes and calculated apparent molecular weights see Table 3.3. Cu1+ is associated with 





















Figure 3.11. Distribution of D1/2-Ccs1 and Cu1+ concentrations in eluted fractions from a gel 
filtration column performed in deoxygenated buffer or the presence of DTT. This shows the 
oligomeric form and location of Cu1+. Only monomeric D1/2-Ccs1 is shown to be present in 
the presence of DTT. Protein (●) and Cu1+ (○) content of gel filtration fractions of D1/2-Ccs1 
in the presence of 0.5 (A and C) and 1.0 (B and D) equivalents Cu1+ in deoxygenated 20 mM 
Hepes pH 7.5 plus 200 mM NaCl (A and B) and the same buffer plus 250 µM DTT (C & D). 
Proteins (100 µM of 200 µL) were injected onto a Superdex 75 10/300 GL column and eluted 
at a flow rate of 0.8 mL/min at room temperature. For elution volumes and calculated 
apparent molecular weights see Table 3.3. Cu1+ is associated with both monomeric and 




















Figure 3.12. Distribution of C17/C20S-Ccs1 and Cu1+ concentrations in eluted fractions from 
a gel filtration column performed in deoxygenated buffer or the presence of DTT. This shows 
the oligomeric form and location of Cu1+. Cu1+ is shown to be associated with both 
monomeric and dimeric C17S/C20S -Ccs1. Protein (●) and Cu1+ (○) content of gel filtration 
fractions of C17S/C20S-Ccs1 in the presence of 0.5 (A and C) and 1.0 (B and D) equivalents 
Cu1+ in deoxygenated 20 mM Hepes pH 7.5 plus 200 mM NaCl (A and B) and the same buffer 
plus 250 µM DTT (C and D). Proteins (100 µM of 200 µL) were injected onto a Superdex 75 
10/300 GL column and eluted at a flow rate of 0.8 mL/min at room temperature. For elution 
volumes and calculated apparent molecular weights see Table 3.3. Cu1+ is associated with 
















Figure 3.13. Gel-filtration chromatograms of Atx1 plus various equivalents of Cu1+ either 
under anaerobic conditions or in the presence of DTT. Plots of absorbance at 280 nm against 
elution volume for reduced apo-Atx1 (black) and Atx1 in the presence of 0.5 (red) and 1.0 
equivalents Cu1+ (blue) in (A) deoxygenated 20 mM Hepes pH 7.5 plus 200 mM NaCl or (B) 
the same buffer plus 250 µM DTT. Proteins (200 µL of 100.0 µM) were injected onto a 
Superdex 75 10/300 GL column and eluted at a flow rate of 0.8 mL/min at room 
temperature. The peak eluting at ≈ 13.2 mL (16 kDa) corresponds to dimer and that eluting 































Figure 3.14. Distribution of Atx1 and Cu1+ in eluted fractions from a gel filtration column. 
Protein (●) and Cu1+ (○) content of fractions (500 µL) of Atx1 in the presence of 0.5 (A and C)  
and 1.0 (B and D) equivalents of Cu1+ in deoxygenated 20 mM Hepes pH 7.5 plus 200 mM 
NaCl (A and B) and the same buffer plus 250 µM DTT (C and D). Proteins (200 µL of 100.0 
µM) were injected onto a Superdex 75 10/300 GL column and eluted at a flow rate of 0.8 
mL/min at room temperature. The peak eluting at ≈ 13.2 mL (16 kDa) corresponds to dimer 











Figure 3.15. Gel-filtration chromatograms of purified Sod1 before and after incubation with 
DTT. Plots of absorbance at 215 nm against elution volume from a  Superdex 75 10/300 GL 
column before (blue) and after (black) overnight incubation of E,E-Sod1 with DTT in 20 mM 
Hepes plus 200 mM NaCl (with 250 µM DTT for the latter sample). Proteins (200 µL of 100.0 
µM) were eluted at a flow rate of 0.8 mL/min at room temperature. The peak eluting at ≈ 




























Figure 3.16. Titrations of Cu1+ into apo-Ccs1 proteins plus BCA to determine Cu1+-binding 
stoichiometries. Plots of [Cu(BCA)2]3- against Cu1+ concentration for reduced (A) apo-WT-
Ccs1, (B) apo-C229S/C231S-Ccs1, (C) apo-C17S/C20S-Ccs1 and (D) apo-D1/2-Ccs1 (all at 10.0 
µM) in the presence of 500 µM BCA in 20 mM Hepes pH 7.5 plus 200 mM NaCl. All solutions 
were prepared in an anaerobic chamber and titrations were performed at room 




















Figure 3.17. Titrations of Cu1+ into apo-Ccs1 proteins plus BCA to determine Cu1+-binding 
stoichiometries. Plots of [Cu(BCA)2]3- against Cu1+ concentration for reduced (A) apo-WT-
Ccs1 and (B) apo-C17S/C20S-Ccs1 (both at 10.0 µM) in the presence of 150 µM BCA in 20 
mM Hepes pH 7.5 plus 200 mM NaCl. All solutions were prepared in an anaerobic chamber 
and titrations were performed at room temperature in anaerobic cuvettes with Cu1+ 






























Figure 3.18. Titrations used to determine the Cu1+ affinities of Ccs1 proteins using BCS. Plots 
of [Cu(BCS)2]3- against added BCS concentration for (A) WT-Ccs1, (B) C229S/C231S-Ccs1 and 
(C) D1/2-Ccs1 using apo-proteins (20 µM) plus 10 µM Cu1+ in 20 mM Hepes pH 7.5 plus 200 
mM NaCl. Lines show fits of the data to Equation 2.1 (Methods 2.17.3). Using an overall 
stability constant (2) of 6.3 x 1020 M-2 gives Kb values of (A) (2.3 ± 0.1) x 1018 M-1, (B) (2.3 ± 
0.1) x 1018 M-1 and (C) (2.4 ± 0.2) x 1018 M-1. All solutions were prepared in an anaerobic 
chamber and titrations were performed at room temperature in anaerobic cuvettes with 

















Figure 3.19. Titrations used to determine the Cu1+ affinities of Ccs1 proteins using BCS. Plots 
of [Cu(BCS2]3- (10 µM) against added reduced apo-C229S/C231S-Ccs1 (A) and  apo-D1/2-Ccs1 
(B) in the presence of an excess 500 µM BCS in 20 mM Hepes pH 7.5 plus 200 mM NaCl. 
Lines show fit of the data to affinity Equation 2.2 (Methods 2.17.3). Using an overall stability 
constant (2) of 6.3 x 1020 M-2 gives Kb values of (A) (2.5 ± 0.2) x 1018 M-1 and (B) (3.2 ± 0.6) x 
1018 M-1. All solutions were prepared in an anaerobic chamber and titrations were 
performed at room temperature in anaerobic cuvettes with Cu1+ additions made using a 




















Figure 3.20. Plot showing the formation of [Cu(BCS)2]3- due to the removal of Cu1+ from 
C17S/C20S-Ccs1 by BCS over time. The removal of Cu1+ from C17S/C20S-Ccs1 (20 µM) plus 
10 µM Cu1+ by BCS (100 µM) in 20 mM Hepes pH 7.5 plus 200 mM NaCl. Protein, BCS and 
Cu1+ stock was prepared in an anaerobic chamber at room temperature. The sample was in 





















Figure 3.21. Titrations used to determine the Cu1+ affinity of C17S/C20S-Ccs1 using BCA. (A) 
A plot of [Cu(BCA)2]3- against added BCA concentration for reduced apo-C17S/C20S-Ccs1 (20 
µM) plus Cu1+ (10 µM) after incubating mixtures for 48 h. (B) A plot of [Cu(BCA)2]3- against 
added reduced apo-C17S/C20S-Ccs1 concentration using 10 µM [Cu(BCA)2]3- with an excess 
of 700 µM BCA. Both experiments were performed in 20 mM Hepes pH 7.5 plus 200 mM 
NaCl at room temperature. Lines show fits of the data to (A) Equation 2.1 and (B) Equation 
2.2 (Methods 2.17.3), using a 2 value for BCA of 5.0 x 1017 M-2 gives Kb values of (A) (1.2 ± 
0.1) x 1018 M-1 and (B) (4.1 ± 0.9) x 1017 M-1. All solutions were prepared in an anaerobic 
chamber and titrations were performed at room temperature in anaerobic cuvettes with 


















Figure 3.22. The removal of Cu1+ from C17S/C20S-Ccs1 by BCA over time. A plot showing the 
formation of [Cu(BCA)2]3- (10 µM) against time for Cu1+-C17S/C20S-Ccs1 (10 µM) plus an 
excess of apo-C17S/C20S-Ccs1 (10 µM) incubated with 1 (blue), 4 (red) and 15 (black) mM 
BCA in 20 mM Hepes pH 7.5 plus 200 mM NaCl. All solutions were prepared in an anaerobic 
chamber and the experiments performed at room temperature in anaerobic cuvettes that 

















Figure 3.23. The stability of the thiols in reduced Ccs1 proteins over time under anaerobic 
conditions. Plots of thiol/protein monomer against time for apo-C17/C20S-Ccs1 (black), Cu1+-
C17/C20S-Ccs1 [0.5 equivalents of Cu1+] (red), apo-C17/C20S-Ccs1 with 4 mM BCA (green) 
and apo-WT-Ccs1 with 4 mM BCA (blue) in 20 mM Hepes pH 7.5 plus 200 mM NaCl. All 
proteins (20 µM) were reduced prior to this experiment in an anaerobic chamber. The 
samples were in anaerobic cuvettes that were returned to the chamber between 





















Figure 3.24. The removal of Cu1+ from WT-Ccs1 in the presence of BCS. Plots of the 
formation of [Cu(BCS)2]3- against time for Cu1+-WT-Ccs1 (10 µM) plus an excess apo-WT-Ccs1 
(10 µM) incubated with 100 (blue), 300 (red) and 1200 (black) µM BCS in 20 mM Hepes pH 
7.5 plus 200 mM NaCl. Data acquired at room temperature for up to 3 (A) and 100 (B) h are 
shown. All solutions were prepared in an anaerobic chamber and the experiments 


























Figure 3.25. The stability of the mixtures formed upon adding apo-C17S/C20S-Ccs1 to 
[Cu(BCA)2]3-. Plots of [Cu(BCA)2]3- against time for 10 µM [Cu(BCA)2]3- plus an excess of BCA 
(700 µM) incubated with 0 (blue), 2 (green), 5 (red) and 10 (black) µM apo-C17S/C20S-Ccs1 
in 20 mM Hepes pH 7.5 plus 200 mM NaCl. Data acquired at room temperature for up to 2 
(A) and 120 (B) h are shown. All solutions were prepared in an anaerobic chamber and the 
experiments performed in anaerobic cuvettes that were returned to the chamber between 































Figure 3.26. Titrations used to determine the Cu1+ affinity of Atx1 using BCS at pH 7.0. (A) A 
plot of [Cu(BCS)2]3- against added BCS concentration using 20 µM reduced apo-Atx1 and 10 
µM Cu1+. (B) A plot of [Cu(BCS)2]3- against added reduced apo-Atx1 concentration using 10 
µM [Cu(BCS)2]3- in the presence of an excess of BCS (100 µM) in 20 mM Hepes pH 7.0 plus 
200 mM NaCl. Lines show the fit of the data to (A) Equation 2.1 and (B) Equation 2.2 
(Methods 2.17.3), and using a 2 of 6.3 x 1017 M-2 for [Cu(BCS)2]3- gives Kb values of (A) (4.1 ± 
0.4) x 1018 M-1 and (B) (4.3 ± 0.3) x 1018 M-1. All solutions were prepared in an anaerobic 
chamber and titrations were performed at room temperature in anaerobic cuvettes with 

























Figure 3.27. Titrations used to determine the Cu1+ affinity of Atx1 using BCS at pH 7.5. (A) A 
plot of [Cu(BCS)2]3- against added BCS concentration for 20.0 µM reduced apo-Atx1 plus 10 
µM Cu1+. (B) A plot of [Cu(BCS)2]3- against added reduced apo-Atx1 concentration using 10 
µM [Cu(BCS)2]3- with an excess of 100 µM BCS in 20 mM Hepes pH 7.5 plus 200 mM NaCl. 
Lines show the fit of the data to (A) Equation 2.1 and B) Equation 2.2 (Methods 2.17.3), and 
using a 2 of 6.3 x 1020 M-2 for [Cu(BCS)2]3- gives Kb values of (A) (1.1 ± 0.1) x 1019 M-1 and (B) 
(1.2 ± 0.7) x 1019 M-1. All solutions were prepared in an anaerobic chamber and titrations 
were performed at room temperature in anaerobic cuvettes with additions made using a 



















Table 3.4. Summary of the average Cu1+ affinities (Kb values) for WT Ccs1 and variants as well 
as Atx1 from S. cerevisiae compared to values for human homologues. 
 
Organism Protein pH Kb (BCA) (M-1)g Kb (BCS) (M-1)g 
S. cerevisiae WT-Ccs1b,e 7.5 - (2.6 ± 1.1) x 1018 
S. cerevisiae WT-Ccs1a,e 7.5 - (2.3 ± 0.1) x 1017 
S. cerevisiae103 WT-Ccs1a,  7.5 - (2.4 ± 0.5) x 1017 
H. sapiens103 WT-CCSa,  7.5 - (5.5 ± 0.6) x 1017 
S. cerevisiae D1/2-Ccs1b,e 7.5 - (2.7 ± 1.0) x 1018 
S. cerevisiae D1/2-Ccs1a,e 7.5 - (2.5 ± 0.6) x 1017 
H. sapiens D1-CCSa,103 7.5 - (5.5 ± 3.5) x 1017 
S. cerevisiae C229S/C231S-Ccs1b,e 7.5 - (2.6 ± 0.5) x 1018 
S. cerevisiae C229S/C231S-Ccs1a,e 7.5 - (2.3 ± 0.1) x 1017 
H. sapiens103 C244S/C246S-CCSa,  7.5 - (4.6 ± 1.0) x 1017 
S. cerevisiae C17S/C20S-Ccs1d,f 7.5 (4.1 ± 0.9) x 1017 - 
S. cerevisiae C17S/C20S-Ccs1c,f 7.5 (4.4 ± 0.8) x 1016 - 
H. sapiens103 C22S/C25S-CCSc,  7.5 (2.7 ± 1.4) x 1016 - 
S. cerevisiae Atx1b,e 7.0 - (4.2 ± 1.4) x 1018 
S. cerevisiae Atx1a,e 7.0 - (4.6 ± 0.5) x 1017 
H. sapiens139 HAH1a,  7.0 - (5.6) x 1017 
S. cerevisiae Atx1b,e 7.5 - (1.2 ± 0.7) x 1019 
S. cerevisiae Atx1a,e 7.5 - (1.1 ± 0.8) x 1018 
 
a Calculated using a log(max) for [Cu(BCS)2]3- of 19.9.138 
b Calculated using a log(max) for [Cu(BCS)2]3- of 20.8.144 
c  Calculated using a log(max) for [Cu(BCA)2]3- of 17.3.138 
d Calculated using a log(max) for [Cu(BCA)2]3- of 17.7.144 
e Obtained from titrations of either BCS or BCA into Cu1+-protein. 
f Determined from titrations of apo-proteins into [Cu(BCA)2]3-. 
















Figure 3.28. SDS-PAGE gel showing the separation of a mixture of Atx1 and C229S/C231S-
Ccs1 by anion exchange chromatography. (A) The Cu1+-Atx1 and apo-C229S/C231S-Ccs1 
mixture, (B) fractions eluted from a HiTrap Q HP column with 20 mM Hepes pH 7.5 that 
contain Atx1, (C) molecular weight marker and (D) fractions eluted with 20 mM Hepes pH 7.5 


























Table 3.5. Protein concentrations from Cu1+ exchange experiments between Atx1 and C229S/C231S-Ccs1, and exchange equilibrium constant 
(Kex values)  after incubation for 1 hr. 
 
 























Cu1+-Atx1 + apo-C229S/C231S-Ccs1 25 25 0 50 17 33 8 42 0.37 
0.17 
apo-Atx1 + Cu1+-C229S/C231S-Ccs1 0 50 25 25 18 32 7 43 0.29 
 
a Concentrations corrected for dilutions 























Table 3.6. Protein concentrations from Cu1+ exchange experiments between Atx1 and C17S/C20S-Ccs1, and exchange equilibrium constant (Kex 
values) after incubation for 1 hr. 
 
 























Cu1+-Atx1 + apo-C17S/C20S-Ccs1 25 25 0 50 20 30 5 45 0.17 
0.03 
apo-Atx1 + Cu1+-C17S/C20S-Ccs1 0 50 25 25 17 33 8 42 0.37 
 
a Concentrations corrected for dilutions. 























Table 3.7. Protein concentrations from Cu1+ exchange experiments between Atx1 and C17S/C20S-Ccs1, and exchange equilibrium constant (Kex 
values) after incubation for 24 h. 
 
 























Cu1+-Atx1 + apo-C17S/C20S-Ccs1 25 25 0 50 21 29 4 46 0.12 
0.03 
apo-Atx1 + Cu1+-C17S/C20S-Ccs1 0 50 25 25 21 29 4 46 0.12 
 
a Concentrations corrected for dilutions. 














Figure 3.29. Visualisation of superoxide dismutase activity using an in-gel assay (Methods 
2.19). A native gel showing the activity of Cu,Zn-Sod1, and the absence of activity for E,Zn-
Sod1 produced by the addition of Zn2+ to E,E-Sod1. For Cu,Zn-Sod1 the total amount of 
protein loaded was varied to determine the optimum amount for activity quantification. 




Figure 3.30. In-gel activity assay (Methods 2.19) of Cu,Zn-Sod1 and E,Zn-Sod1 compared to a 
standard protein. A native gel showing the superoxide dismutase activity of Cu,Zn-Sod1, and 
absence of activity of E,Zn-Sod1, as well as different total amounts of bovine erythrocyte 
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Figure 3.31. In-gel Cu,Zn-Sod1 activity assay (Methods 2.19) used to analyse the metalation 
of E,Zn-Sod1. A native gel showing Cu,Zn-Sod1 activity for a Zn-Sod1 sample (100 ng Sod1 
loaded in gel lane A and B) incubated with (A) and without (B) a Cu2+ salt. Cu1+-loaded forms 
of WT and variant Ccs1 proteins were loaded in gel lanes (C-F) without incubation with 
Sod1. Active Sod1 is indicated by white bands in the image. All solutions were prepared in 
an anaerobic chamber and all proteins were reduced prior to use. E,Zn-Sod1 and Cu,Zn-Sod1 
were prepared by the addition of equal quantities of E,E-Sod1, ZnSO4 and/or Cu2+(NO3)2.  
Apo-Ccs1 proteins and Cu1+ (1 equivalent) were incubated anaerobically for 30 mins. The 
Reaction mixtures consisted of 5 µM E,Zn-Sod1, 5 µM Cu1+-Ccs1, 100 µM EDTA and 100 µM 
BCS. Samples were exposed to air, incubated at 37 oC for 1 h and loaded onto a NATIVE-
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Figure 3.32. In-gel Cu,Zn-Sod1 activity assay (Methods 2.19) used to analyse the metalation 
of E,Zn-Sod1. A native gel showing Cu,Zn-Sod1 activity for Zn-Sod1 samples (100 ng Sod1 
loaded in each gel lane) incubated with a Cu2+ salt and Cu1+-loaded forms of WT and variant 
Ccs1 proteins. Active Sod1 is indicated by white bands in the image. All solutions were 
prepared in an anaerobic chamber and all proteins were reduced prior to use. E,Zn-Sod1 
and Cu,Zn-Sod1 were prepared by the addition of equal quantities of E,E-Sod1, ZnSO4 
and/or Cu2+(NO3)2.  Apo-Ccs1 proteins and Cu1+ (1 equivalent) were incubated anaerobically 
for 30 mins prior to being mixed with E,Zn-Sod1. The Reaction mixtures consisted of 5 µM 
E,Zn-Sod1, 5 µM Cu1+-Ccs1, 100 µM EDTA and 100 µM BCS. Once combined, samples were 















Figure 3.33. In-gel Cu,Zn-Sod1 activity assay (Methods 2.19) used to analyse the metalation 
of E,Zn-Sod1. A native gel showing Cu,Zn-Sod1 activity for Zn-Sod1 samples (stated amount 
of Sod1 loaded in each gel lane) incubated with Cu1+-loaded forms of (A) WT-Ccs1 and (B) 
C17S/C20S-Ccs1 . Active Sod1 is indicated by white bands in the image. All solutions were 
prepared in an anaerobic chamber and all proteins were reduced prior to use. E,Zn-Sod1 
was prepared by the addition of an equal quantity of E,E-Sod1 and ZnSO4.  Apo-Ccs1 
proteins and Cu1+ (1 equivalent) were incubated anaerobically for 30 mins prior to being 
mixed with E,Zn-Sod1. The Reaction mixtures consisted of 5 µM E,Zn-Sod1, 5 µM Cu1+-Ccs1, 
100 µM EDTA and 100 µM BCS. Once combined, samples were exposed to air, incubated at 
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Copper is essential for eukaryotic cells to function optimally and is employed for a variety of 
purposes such as involvement in the key machinery of energy production.59-61, 154 
Interestingly, the redox characteristic of copper that is exploited by many biological systems 
is also highly damaging to cellular components and copper can cause a variety of toxic issues 
for cells.15, 16 To overcome this difficulty, a complex network of copper trafficking pathways 
has evolved within eukaryotic cells to strictly control the transport of copper to its required 
locations, whilst also limiting its exposure and damage to organelles. 
Copper chaperones are integral machinery in the copper trafficking pathways and not only 
sequester copper to prevent damage, but also deliver copper to specific targets such as 
copper-requiring proteins. This process of copper transfer from chaperone to target protein 
can also act as a crucial step in the activation or maturation of these proteins and is 
therefore required for correct functioning. If the delivery of copper is interrupted or the 
transfer is erroneous, this can have an adverse knock-on effect further downstream of the 
pathway or the function of the target protein can be lost or subverted. Deviations in the 
function of some of the key proteins in the cellular copper network are associated with 
human diseases. These include Menkes and Wilson’s disease (see section 8.1.3 of 
Introduction) and amyotrophic lateral sclerosis (ALS) (see section 1.6.5 of Introduction). The 
biological importance of the copper chaperones has motivated the study of these integral 
components and associated pathways in order to further understand the intricacies of the 
cellular copper networks, clarify the source of any modifications to the correct functioning 
of key proteins and identify any potential therapeutic targets.  For example, the 
identification of new therapeutic targets is highly desirable for the treatment and early 
diagnosis of ALS. Currently, there is only one drug licensed to treat ALS in the UK155 and the 
effect on the survival outcome has been shown in randomised clinical trials to improve by 2-
3 months.156 
The complexities of the copper trafficking networks can make it challenging to study a 
particular process in isolation due to subsidiary pathways. This has been shown to exist in 
the case of SOD1 activation in humans due to a CCS-independent activation pathway that 
does not exist in S. cerevisiae (see section 1.11 of the Introduction). Therefore, in order to 
study the activation of this protein by its metallochaperone, the yeast network presents the 




not be concealed by alternate sources of Ccs1-independent activation in yeast, the 
dependence on Ccs1 only may cause differences in the activation mechanism as compared 
to the human system thereby identifying key steps in the process.  
Ccs1 contains seven Cys residues, four of which are located in D1, including two involved in 
the CXXC copper-binding motif, and another two that form a disulfide bridge.  One cysteine 
is located in D2, and two more are in the CXC copper-binding motif of D3 (Figure 4.2).92  The 
detection of only 4.7 ± 0.4 free thiols for Ccs1-WT after reduction of the protein with DTT 
suggests that the protein is highly sensitive to oxidation and the formation of disulphide 
bonds, and some cysteine residues are not solvent exposed.  This value is also consistent 
with the previous range of 4.5 - 5.0 free thiols determined for Ccs1.103  The mutants 
C17S/C20S-Ccs1, C229S/C231S-Ccs1 and D1/2-Ccs1 gave 2.7 ± 0.5, 3.0 ± 0.5 and 2.9 ± 0.1 
thiols per monomer respectively.  The measurement of two thiols less for each of the Ccs1 
mutants is expected since they all feature the loss of two Cys residues.   
The requirement of a reducing DTT treatment in order to detect the free thiols of Ccs1 
indicates that oxidation of the Cys residues of Ccs1 occurs in the presence of oxygen.  
Oxidation may cause the formation of intra- or inter-molecular disulfide bonds, causing a 
loss of ability to bind copper and the formation of oligomers.  To avoid possible oxygen-
induced oligomerization and maintain the reduced thiol state of the Ccs1 Cys residues, 
samples were prepared in anaerobic chamber and gel filtration chromatography was 
performed in buffer degassed and bubbled with nitrogen (Method 2.7.2).  Under these 
anaerobic conditions, gel filtration data shows that in the absence of Cu1+, WT-Ccs1 is 
predominantly monomeric with 11 % of the protein forming a dimer (Figure 3.5 A).  This is 
distinct from human CCS1 which is shown to be a dimer in the apo-form by gel filtration 
performed at pH 6.5.103  A reducing environment decreased the proportion of dimer 
observed for apo-WT-Ccs1 to 8 % although dimerization was not eliminated (Figure 3.5 A).  
C229S/C231S-Ccs1 and D1/2-Ccs1 also appear as predominantly monomeric with only 4 and 
3 % dimer formed respectively in the absence of Cu1+ and DTT (Figure 3.5 B & C).  The 
presence of DTT eliminated the dimeric form in both cases and only monomer is observed.  
Interestingly, C17S/C20S-Ccs1 appears more prone to dimerization since, in the absence of 
Cu1+ and DTT, an equal amount of dimer and monomer are observed (Figure 3.5 D).  




dimer from 49 to 5 %.  The decrease in the amount of dimer in the apo-proteins by DTT 
indicates that this is most probably due to the formation of intermolecular disulfide bridges.  
The higher proportion of dimer observed for C17S/C20S-Ccs1 compared to the other Ccs1 
proteins suggests that the D3 CXC motif is primarily involved in intermolecular disulfide 
formation.  Oxidation may not be the only influence, although the Cys residues of D1 are 
solvent exposed (Figure 4.1), they are fixed in position by the secondary structure of Ccs1. 
Alternatively, the irregular structure of D3 may afford flexibility which enables its CXC motif 
to come into contact with other D3 sites more readily than those of D1.  Also, the pKa values 
of Cys residues are tuned by their surrounding environment and can influence the 
nucleophilicity of the thiolate group.157  The fixed position of the D1 Cys residues compared 
to the ability of D3 to move provides different environments that may alter the pKa values of 
the Cu1+-binding Cys residues. The pKa values of the Cys residues in D3 may be higher than 





Figure 4.1. The surface structure of the Ccs1 protein. Crystal structure of S. cerevisiae Ccs1 
in which only D1 (magenta) and D2 (blue) are observed.  The metal-binding Cys residues of 
D1 are shown in yellow and are solvent exposed. Image created using PyMol v1.3 from the 




Upon the addition of Cu1+, the gel filtration data of WT-Ccs1 shows that the proportion of 
dimer increases (Figure 3.6 A).  It has been reported previously that in the presence of Cu1+, 
Ccs1 forms a mixture of monomer and dimer.103, 104, 158  In the presence of Cu1+, human CCS1 
is found in dimeric and tetrameric forms.103  Gel filtration experiments in buffer containing 
DTT provides a reducing environment and eliminates the formation of dimers due to 
oxidation which would have otherwise been attributed to the presence of Cu1+ (Figure 3.6 B) 
.  A concentration of 250 µM DTT was utilised as this is sufficiently low that competition with 
the Ccs1 proteins for Cu1+ is not an issue.  The affinity of DTT for Cu1+ has been estimated as 
Kb = 1015.3 M-1 at pH 7.3,138 which is three orders of magnitude lower than the affinity of WT-
Ccs1 measured here, (2.6 ± 1.1) x 1018 M-1. 
The formation of dimeric WT-Ccs1 is not affected by the presence of DTT, indicating that 
dimerization is not due to intermolecular disulfide formation and is related to the binding of 
Cu1+.  Analysis of the eluted fractions from the gel filtration column to measure protein and 
Cu1+ concentrations can determine whether Cu1+ is associated with monomeric or dimeric 
protein.  Cu1+ is found to associate with both the monomeric and dimeric forms of WT-Ccs1 
(Figure 3.8) although at greater than 1 equivalent, Cu1+ preferentially binds to the 
monomeric protein (Figure 3.8 D).  In the presence of DTT, the WT-Ccs1 monomer/dimer 
peaks are not resolved, however Cu1+ appears to be located at elution volumes associated 
with the dimeric protein up to a Cu1+ concentration of one equivalent (Figure 3.9 A & B).  At 
Cu1+ concentrations higher than one equivalent, the protein and Cu1+ content is not resolved 
and it is impossible to distinguish between monomer and dimer (Figure 3.9 C & D).   
Similar to WT-Ccs1, C229S/C231S-Ccs1 and D1/2-Ccs1 also show an increase in the 
proportion of dimer as Cu1+ is added. Dimerization of C229S/C231S-Ccs1 increases from 4 to 
16 and 34 % dimer for apo-protein, 0.5 and 1.0 equivalent of Cu1+ respectively (Figure 3.7 A). 
In addition, dimerization of D1/2-Ccs1 increases from 4 to 13 and 33 % dimer for apo-
protein, 0.5 and 1.0 equivalent of Cu1+ respectively (Figure 3.7 C).   Also, Cu1+ associates with 
both dimer and monomer (Figure 3.10 A & B, Figure 3.11 A & B).  Dimerization of Cu1+-
C229S/C231S-Ccs1 and Cu1+-D1/2-Ccs1 is completely eliminated in the presence of DTT 
(Figure 3.7 B & D) and Cu1+ is found associated with the monomer (Figure 3.10 C & D, Figure 
3.11 C & D).  The elimination of the dimer by DTT suggests that dimerization is disulfide 




concentration upon the addition of Cu1+ is also observed with C17S/C20S-Ccs1.  
Dimerization of C17S/C20S-Ccs1 increases from 49 to 61 and 77 % dimer for apo-protein, 0.5 
and 1.0 equivalent of Cu1+ respectively (Figure 3.7 E), and this is not eliminated by the 
presence of DTT (Figure 3.7 F).  There is an overall reduction (5, 49 and 59 % dimer for apo-
protein, 0.5 and 1.0 equivalent of Cu1+ respectively) but dimeric Cu1+-C17S/C20S-Ccs1 
remains a major form.  This suggests that dimerization through D3 is not linked to disulfide 
formation and is related to the presence of Cu1+.  C17S/C20S-Ccs1 is found to preferentially 
bind Cu1+ in the dimeric form (Figure 3.12).  This is not affected by a reducing environment 
and could be due to an overall higher proportion of the dimeric protein. 
The gel filtration data shows that Ccs1 is able to form dimers through disulfide linking of 
both the Cys residues of the D1 and D3 site, and the dimeric protein is able to bind Cu1+.  
Dimerization through D1 appears to occur by disulfide bridges only, whereas D3 
dimerization occurs through Cu1+ binding.  The appearance of homodimers in the crystal 
structures of both yeast Ccs192 and human CCS98 and complementary residues along the D2-
D2 interface implicated D2 as a site of dimerization similar to dimerization observed with 
SOD1.  However, if D2-D2 interactions were producing the dimerization observed for Cu1+-
C17S/C20S-Ccs1 in the presence of DTT, this would also be seen with Cu1+-C229S/C231S-
Ccs1 and Cu1+-D1/2-Ccs1 as they also contain D2, but dimerization is absent.  Dimerization 
of human CCS was found to include multinuclear copper clusters which occurs through D3 
only.134, 159  If dimerization does occur at D3 as a copper cluster, this could have mechanistic 
implications since D3 of yeast Ccs1 is regarded to be the location of copper transfer to 
Sod1104 whereas this is D1 in human CCS.83 
Overexpressed D2/3-Ccs1 was shown to consist of unfolded protein by far-UV CD 
spectroscopy (Figure 3.1) and the measured molecular weight is 191 Da less (60 Da less from 
N-terminal methionine) than the expected value (Table 3.1) which is not easily explained.  
This was highly unexpected since D2 of Ccs1 and Sod1 share a similar structure, and 
recombinant Sod1 is folded (Figure 3.4).  Purified D1/2-Ccs1 is shown to have a very similar 
structure to WT-Ccs1 (Figure 3.1) by far-UV CD spectroscopy.  This was achieved by 
incubation of E. coli at 16 oC rather than 37 oC to avoid the production of insoluble protein 
(Method 2.10.2).  The amino acid sequence of D2/3-Ccs1 consisted of residue 72 to 249, 




the crystal structure92 of Ccs1 there is a hydrogen bond between residues 72 and 220 
(Figure 4.2) which may provide stability to the secondary structure of the protein.  
Previously, a Ccs1 mutant lacking D1 was cloned from residue 75 and was able to activate 
Sod1 successfully, suggesting that the protein folded correctly, although no in vitro 
characterization of the purified protein was reported.104  Why D2/3-Ccs1 does not fold 
correctly could be due to unknown consequences of including the linking residues. 
Stoichiometry titrations show that in the presence of the competitive ligand BCA at 500 µM, 
C229S/C231S-Ccs1 and D1/2-Ccs1 bind ≈ 1 equivalent of Cu1+ whilst WT-Ccs1 binds more 
than one equivalent Cu1+ (Figure 3.16).  C17S/C20S-Ccs1 shows weak competition with BCS 
for Cu1+ and an accurate binding stoichiometry determination is not possible.  Upon 
reduction of BCA to 150 µM, C17S/C20S-Ccs1 is found to bind ≈ 1 equivalent of Cu1+ (Figure 
3.17 B).  Similarly, reduction of the BCA concentration also shows that WT-Ccs1 binds ≈ 2 
equivalents of Cu1+ (Figure 3.17 A).  This is expected since WT-Ccs1 features two potential 
Cu1+ binding sites and each of the Ccs1 variants features the loss of one of these sites.  The 
ability of the Ccs1 mutants to bind Cu1+ indicates that the loss of the cysteine residues at 
one of the Cu1+ binding sites, or the loss of D3 in D1/2-Ccs1, does not affect Cu1+ binding by 
the remaining site, and that Cu1+ is bound independently.   This data suggests a weaker 
affinity of D3 for Cu1+ than that of D1 since a lower BCA concentration is needed for 
effective competition for Cu1+ with C17S/C20S-Ccs1 than with C229S/C231S-Ccs1 and D1/2-
Ccs1.   
Competition titrations with BCS were performed to measure the affinity (Kb value) of the 
proteins for Cu1+.  Titrations with WT-Ccs1, C229S/C231S-Ccs1 and D1/2-Ccs1 in the 
presence of 0.5 equivalents of Cu1+ provided Kb values of (2.6 ± 1.1) x 1018 M-1, (2.6 ± 0.5) x 
1018 M-1 and (2.7 ± 1.0) x 1018 respectively (Table 3.4).  Experiments involving titrations of 
BCS into Cu1+-protein (Figure 3.18) and titrations of apo-protein into [Cu(BCS)2]3- (Figure 
3.19) gave consistent affinity values.  This indicates that equilibrium was reached and the 
affinity values measured are accurate.  These values are essentially the same for all three 
proteins and suggests that the Cu1+ is bound by the same site in all proteins.  This can only 
be the copper binding motif of D1 since C229S/C231S-Ccs1 and D1/2-Ccs1 only contain this 




Measurement of the copper binding site in D3 by use of the C17S/C20S-Ccs1 mutant proved 
more difficult.  A relatively small concentration of BCS removed a large proportion of Cu1+ 
from C17S/C20S-Ccs1 providing insufficient competition for affinity titrations (Figure 3.20).  
This had also been observed for the equivalent human mutant (C244S/C246S-CCS), 
therefore experiments with BCA were performed due to the lower affinity for Cu1+ than BCS 
by 2.6 orders of magnitude, making it more suitable for effective competition with the D3 
site.138  Affinity experiments with human C244S/C246S-CCS involving additions of BCA to 
Cu1+-protein also required much longer experiment time-frames (48 hrs).  This approach, 
applied to C17S/C20S-Ccs1, resulted in prolonged removal of Cu1+ from the protein by BCA 
after the 48 hr experiment time-frame (Figure 3.22).  This suggests that a lower 
concentration of BCA is required to effectively complete with C17S/C20S-Ccs1 for Cu1+, 
indicating that the affinity of the Cu1+-binding site of D3 is weaker than the human site.  
Interestingly, the stability of affinity titrations involving additions of apo-C17S/C20S-Ccs1 
into [Cu(BCA)2]3- over time indicated that equilibrium was achieved within the time-frame of 
these experiments (Figure 3.25).  These provided a measurement of the affinity as (4.1 ± 
0.9) x 1017 M-1. 
The affinity measurements are consistent with the implication from the stoichiometry 
titrations that the Cu1+-binding site of D3 is weaker than that of D1.  The affinity of 
C229S/C231-Ccs1 is 3 times higher than that of C17S/C20S-Ccs1.  This trend agrees with the 
higher affinity of D1 than D3 measured for human CCS.  Plots of the affinity data using 
previous BCS/BCA βmax values provides affinity values for WT-Ccs1, C229S/C231S-Ccs1 and 
C17S/C20S-Ccs1  which are comparable to previously calculated literature values for the 
human proteins (Table 3.4).103  Comparison of the yeast and human proteins containing the 
D1 site only shows that the affinity of the D1 copper-binding site of Ccs1 is half the value of 
the equivalent site for Cu1+ in the human protein.  Interestingly, the proteins containing the 
D3 site only show that the affinity of the D3 copper-binding site of Ccs1 is ≈ twice the value 
of the equivalent site for Cu1+ in the human protein.  This highlights that although the 
affinity for Cu1+ of the D1 site of Ccs1 is higher than that of D3, this difference is not as 
pronounced as the equivalent domains in human CCS.  These results are not able to confirm 
the hypothesis that the mechanism of copper transfer between Ccs1 and Sod1 is 




The higher affinity of D1 for Cu1+ than D3 further complicates the hypothesis of a difference 
between the human and yeast mechanism for Sod1 activation (Figure 4.3).  The higher 
affinity of D1 agrees with the site of Cu1+ transfer to SOD1 in humans having been 
established as D1, and D3 essential for the formation of the disulfide bond.82, 83  However, 
this is in contradiction with D3 of yeast Ccs1 being found to be critical for copper transfer in 
yeast.104  Due to the flexibility of D3 it has been proposed that D3 is able to obtain copper 
from D1.75, 105, 106  Therefore the role of D1 would be expected to involve Cu1+ acquisition 
and transfer to D3 for insertion into SOD1, however the increased affinity of D1 for Cu1+ 
compared to D3 would make this thermodynamically unfavourable.  Copper transfer 
occurring at D1 in humans makes it hard to justify that with a similarly higher affinity of Ccs1 
D1 than D3, copper transfer actually occurs through D3.  However, there are differences in 
the two systems of humans and yeast.  There are structural differences between the 
proteins, with human CCS possessing the zinc-binding loop and electrostatic channel loop of 
SOD98 whereas in yeast Ccs1 this is absent.92  Also, the oligomerisation of the human and 
yeast proteins are different.  Human CCS adopts a dimeric form as apo-protein and a 
tetramer in the presence of Cu1+,159 whereas yeast Ccs1 exists primarily as a monomer in the 
apo-form and dimerizes upon the addition of Cu1+.  In yeast, activation of Sod1 is dependent 
on Ccs1,133 whereas in humans SOD1 can be activated independently of CCS1.132, 133, 160  
Also, some organisms express CCS of which the D1 copper binding motif is missing and is still 
able to activate SOD under copper abundant conditions.95, 160  These differences of the 
human and yeast copper chaperones may actually demand a different mechanism of Sod1 
activation between the two systems.  Until further evidence towards the mechanism of 
action is provided, the similarities or differences of CCS1 and Ccs1 will remain unclear. 
Sod1 contains two cysteines, both of which are located at the active site.74  The detection of 
1.8 ± 0.2 free thiols per monomer for Sod1 after reduction of the protein with DTT shows 
that the cysteines are solvent exposed and can be reduced. 
Purified E,Zn-Sod1 was shown by analytical gel filtration to be dimeric in the presence of 
DTT  and monomeric protein was only observed after incubation with DTT overnight (Figure 
3.15).  This agrees with previous experiments in which the major determinant of Sod1 
dimerization was found to be the thiol status, with E,Zn-Sod1SH largely existing as a 




dimerization of hSOD1 requires not only the reduction of the disulfide, but also at least 
partial loss of the catalytic metals.80, 152, 153  The disulfide between Cys57 and Cys146 
covalently anchors the conformation of an interface loop which is reoriented upon 
reduction of the disulfide, thereby disturbing the dimer interface.  Addition of the catalytic 
metals copper and zinc restores the loop conformation and the dimer interface.  It is 
interesting that the human E,Zn-SOD1SH protein form favours the dimeric state, whereas the 
yeast E,Z-Sod1SH protein form prefers the monomeric state.  This difference in the behaviour 
of human and yeast proteins has been hypothesized to be associated to two proline 
residues located near the disulfide which are present in the human protein but not in the 
yeast protein.  These proline residues have already been linked to the CCS-independent 
activation pathways which show differences between the human and yeast proteins.133   
The purified Sod1 protein was shown to be activated by incubation with metal salts and 
Sod1 activity was successfully visualised by means of an NBT assay (Figure 3.29).  Only the 
fully metallated Cu,Zn-Sod1S-S displayed activation, and partial metalation by zinc only (E,Zn-
Sod1S-S) was unable to perform any catalytic activity.  Cu1+-loaded Ccs1 proteins do not 
provide a positive activity band in the NBT assay, therefore positive activity bands are only 
produced as a result of a fully active  Sod1.  Sod1 activity is observed after incubation with 
all Cu1+-Ccs1 variants (Figure 3.32).  WT-Ccs1 provides a level of Sod1 activation similar to 
that observed from Sod1 fully-metallated by metal salts, whereas the Ccs1 mutants all 
provide lower activation levels.  However, Cu1+-C17S/C20S-Ccs1 shows a greater level of 
Sod1 activation than Cu1+-C229S/C231S-Ccs1 and Cu1+-D1/2-Ccs1, which show equal levels 
of Sod1 activation. 
The observation of Sod1 activity from incubation with Cu1+-C17S/C20S-Ccs1, at a lower level 
to WT-Ccs1 is consistent with previous in vivo data.104  However, the low level of activation 
observed after incubation with Cu1+-Ccs1 mutants containing the D1 copper-binding site 
only (C229S/C231S-Ccs1 and D1/2-Ccs1) is unexpected.  Previously, a D1/2-Ccs1 mutant was 
unable to activate Sod1 in vivo and D1 was designated as being necessary under copper 
limiting conditions only.104  These experiments involved the expression of specific mutants 
in yeast strains with a deleted Ccs1 gene.  Furthermore, there are issues inherent in the NBT 
assay.  Activity of Sod1 is only achieved upon the maturation of Sod1 to a fully mature 




formation of the disulfide.  The NBT assay only provides a positive response to complete 
activation and does not distinguish whether disulfide formation or copper transfer alone has 
occurred.   
The observation of apo-Atx1 dimers in the presence of a reducing environment indicates 
that dimerization does not occur through intermolecular disulfide bridges, and indicates an 
alternative interaction. One possibility is a similar recognition process as the electrostatic 
forces between Atx1 and Ccc2a, as Ccc2a shares a similar structure to Atx1,110 two Atx1 
monomers may assemble in a similar manner. However, the addition of Cu1+ shifts the 
oligomeric state of Atx1 to a monomer suggesting that dimerization is linked to interactions 
of the protein with Cu1+. It has been reported previously that the predominant form of Atx1 
is a monomer regardless of the presence of Cu1+,31 which conflicts with the results shown 
here, although dimerization of Atx1 has been shown with the incorporation of excess GSH.53 
The affinities measured for Atx1 were replotted using a previous BCS βmax value providing 
affinity values which are comparable to previously calculated literature values for the yeast 
and human proteins (Table 3.4).  The affinity values match those previously reported,140, 141 
however, the use of the current BCS βmax value provide affinities ≈ an order of magnitude 
higher than those using the previous value.  The two differing approaches used here to 
measure the affinity of Atx1 for Cu1+ are consistent, which indicates that equilibrium was 
reached and confirms the validity of these methods. The increase in the Kb value (> 3-fold) 
from pH 7.0 to 7.5 is most probably due to protonation of the Cysteine residues within the 
copper binding motif which has been shown extensively within the analogous human 
pathway.139  The dependence of Cu1+ affinities on pH has been determined as a result of 
competition between H+ and Cu1+ for the cysteine residues of the copper binding motifs.139, 
161 
The calculation of protein affinities is important in understanding the thermodynamics of 
Cu1+ distribution amongst copper-trafficking pathways within cells, and the transfer of 
copper between partner proteins.  It has been suggested that relative affinities drives Cu1+ 
along particular routes to target proteins.137  However, this thermodynamic driving force 
was found to be unfavourable at pH < 7.0,139 and also not true in the prokaryote 
Synechocystis which designates the affinity of proteins as not the determining factor in 




It has been suggested that with the similar affinities of Ccs1 and Atx1, along with similar 
protein levels,17, 162 that thermodynamically these metallo-chaperones may be able to 
compete for copper.  Due to the higher affinity of Atx1 to both Ccs1 domains, the Ktheo 
values calculated suggest that the majority of Cu1+ will be bound at equilibrium to Atx1.  The 
Ktheo values also indicate that this reaction quotient will be more pronounced with 
C17S/C20S-Ccs1 than C229S/C231S-Ccs1 due to the lower affinity of D3 compared with D1.     
Exchange experiments have shown that Cu1+ transfer between Atx1 and Ccs1 does occur in 
vitro and supports the hypothesis that Ccs1 and Atx1 can compete for copper.  Interestingly, 
this transfer can take place at both the copper binding sites of D1 and D3-Ccs1, although 
exchange to D3 is very limited.  These exchange experiments validate the trend seen with 
the affinity values, that D1 has a higher affinity for Cu1+ than D3 since the Kex value for 
exchange with C17S/C20S-Ccs1 is lower than that with C229S/C231S-Ccs1.  The product 
distribution between Atx1 and C17S/C20S-Ccs1 in both directions required more time than 
with C229S/C231S-Ccs1 to equilibrate.  Incubation for 24 hrs provided consistent Kex values 
for exchange in both directions indicating that equilibrium had been reached.  C17S/C20S-
Ccs1 has shown similar requirements for longer experiment times when measuring the 
affinity, which demonstrates that this is a characteristic of the binding site in D3-Ccs1 rather 
than an issue with Atx1. 
The exchange of Cu1+ between Atx1 and Ccs1 suggests that the distribution of copper along 
a particular route could be selected depending on the affinities and concentrations of 
proteins present at the copper pool.  This would indicate that copper is not collected 
directly from Ctr1 because distribution would depend on preferential interactions at the 
chaperone-transporter interface and not interactions between Ccs1 and Atx1.  Also, in vivo 
studies in S. cerevisiae have indicated that Ccs1 and Atx1 do not collect copper directly from 
metal transporters,163 however, Ctr1 is able to transfer Cu1+ to Atx1 in vitro.130  Nonetheless, 
even if proteins initially collected copper from Ctr1 or separate locations, the process of 
exchange could be a downstream method for allocating copper along a particular route. 
The results presented in this work have provided a quantitative ability to compare the 
human CCS and yeast Ccs1 proteins through the copper affinity values of the copper-binding 
sites and can be used to make informed mechanistic implications.  These measured values 




understanding of the thermodynamic distribution of copper amongst the cellular trafficking 
pathways.  Additionally, differences in the affinity values for copper between the human 
and yeast protein have been confirmed and quantified which supports the hypothesis that 
the mechanisms of action differ.   The differences in the proposed mechanisms of activation 
between the human and yeast systems are juxtaposed in Figure 4.3.  Although this work has 
shown a difference between the copper affinities of the human and yeast proteins, the 
spread of the affinities between the two protein domains is shown to be similar, which 
complicates the ability to explain why the mechanism of copper transfer between the two 
systems is different.  The evidence provided here as visualised by the NBT assay showing 
that D3 of Ccs1 is able to activate Sod1 to the same level as the wild-type protein indicates a 
fundamental difference between the human and yeast proteins.  This supports the 
proposed mechanism of Sod1 activation in yeast. However, the observed ability of D1 of 
Ccs1 to also activate Sod1 to a lesser extent has called into question either the validity of 
the NBT assay method or highlighted an issue with applying in vitro experiments to the in 
vivo environment. This result contradicts a previous literature experiment and future work 
investigating the reliability of the assay method is required. Definitive confirmation of 
whether D1 of Ccs1 is able to activate Sod1 is critical in order to confirm the fundamental 
differences between the human and yeast mechanisms. Experimental methodology that is 
able to distinguish the steps of activation; copper transfer and disulphide formation, should 
be explored going forward. The elucidation of the role each domain of the yeast Ccs1 plays 
in these steps would better inform the suggested mechanism in yeast. 
Determination of the affinity value for Atx1 has provided a quantitative ability to compare 
the value measured for Ccs1 and develop the discussion in regards to the hypothesis of 
whether these two proteins can compete for copper.  The exchange of copper between 
Ccs1 and Atx1 has been shown to occur in vitro and is consistent with the expected ability 
denoted by the affinity values.  These results suggest that copper metallochaperones from 
separate copper trafficking pathways should be able to compete for and exchange copper in 
a cellular environment.  These findings also contribute to the overall considerations of how 
cells may allocate and distribute copper along the complex transport pathways.  The logical 
step forward is to investigate these isolated in vitro results in the cellular environment to 




Atx1 and Ccs1 to exchange copper raises the question of whether other metallochaperones 
are also able to exchange copper. Similar exchange experiments with proteins from other 
copper trafficking pathways, such as the delivery of copper into the mitochondria, would 
indicate whether this metal exchange ability is a general method to distribute copper within 
yeast cells or is limited to Atx1 and Ccs1. Furthermore, confirmation that Atx1 and Ccs1 are 
able to exchange copper does not establish whether these proteins are exposed to the same 
copper pool within the cell and ultimately compete for copper. Future work to identify the 
sources of copper for Atx1 and Ccs1 will confirm if competition between these copper 





















C17S/C20S-Ccs1        MTTNDTYEATYAIPMHSENSVNDIKACLKNVPGINSLNFDIEQQIMSVESSVAPSTIINT 60 
D2/3-Ccs1             ------------------------------------------------------------ 0 
C229S/C231S-Ccs1      MTTNDTYEATYAIPMHCENCVNDIKACLKNVPGINSLNFDIEQQIMSVESSVAPSTIINT 60 
WT-Ccs1               MTTNDTYEATYAIPMHCENCVNDIKACLKNVPGINSLNFDIEQQIMSVESSVAPSTIINT 60 
D1/2-Ccs1             MTTNDTYEATYAIPMHCENCVNDIKACLKNVPGINSLNFDIEQQIMSVESSVAPSTIINT 60 
                                                                                   
 
C17S/C20S-Ccs1        LRNCGKDAIIRGAGKPNSSAVAILETFQKYTIDQKKDTAVRGLARIVQVGENKTLFDITV 120 
D2/3-Ccs1             -----------GAGKPNSSAVAILETFQKYTIDQKKDTAVRGLARIVQVGENKTLFDITV 49 
C229S/C231S-Ccs1      LRNCGKDAIIRGAGKPNSSAVAILETFQKYTIDQKKDTAVRGLARIVQVGENKTLFDITV 120 
WT-Ccs1               LRNCGKDAIIRGAGKPNSSAVAILETFQKYTIDQKKDTAVRGLARIVQVGENKTLFDITV 120 
D1/2-Ccs1             LRNCGKDAIIRGAGKPNSSAVAILETFQKYTIDQKKDTAVRGLARIVQVGENKTLFDITV 120 
                                  
 
C17S/C20S-Ccs1        NGVPEAGNYHASIHEKGDVSKGVESTGKVWHKFDEPIECFNESDLGKNLYSGKTFLSAPL 180 
D2/3-Ccs1             NGVPEAGNYHASIHEKGDVSKGVESTGKVWHKFDEPIECFNESDLGKNLYSGKTFLSAPL 109 
C229S/C231S-Ccs1      NGVPEAGNYHASIHEKGDVSKGVESTGKVWHKFDEPIECFNESDLGKNLYSGKTFLSAPL 180 
WT-Ccs1               NGVPEAGNYHASIHEKGDVSKGVESTGKVWHKFDEPIECFNESDLGKNLYSGKTFLSAPL 180 
D1/2-Ccs1             NGVPEAGNYHASIHEKGDVSKGVESTGKVWHKFDEPIECFNESDLGKNLYSGKTFLSAPL 180 
                       
 
C17S/C20S-Ccs1        PTWQLIGRSFVISKSLNHPENEPSSVKDYSFLGVIARSAGVWENNKQVCACTGKTVWEER 240 
D2/3-Ccs1             PTWQLIGRSFVISKSLNHPENEPSSVKDYSFLGVIARSAGVWENNKQVCACTGKTVWEER 169 
C229S/C231S-Ccs1      PTWQLIGRSFVISKSLNHPENEPSSVKDYSFLGVIARSAGVWENNKQVSASTGKTVWEER 240 
WT-Ccs1               PTWQLIGRSFVISKSLNHPENEPSSVKDYSFLGVIARSAGVWENNKQVCACTGKTVWEER 240 
D1/2-Ccs1             PTWQLIGRSFVISKSLNHPENEPSSVKDYSFLGVIARSAGVW------------------ 222 
                                         
 
C17S/C20S-Ccs1        KDALANNIK 249 
D2/3-Ccs1             KDALANNIK 178 
C229S/C231S-Ccs1      KDALANNIK 249 
WT-Ccs1               KDALANNIK 249 
D1/2-Ccs1             --------- 222 
 
Figure 4.2  Sequence alignment of the WT and Ccs1 variants used throughout this thesis. 
The Cu1+-binding Cys residues are highlighted in yellow and the remaining Cys residues are 
highlighted in blue. Two residues that are hydrogen-bonded in the crystal structure92 are 













Figure 4.3. A comparison of the activation of Cu,Zn-superoxide dismutase by the protein’s Cu1+-metallochaperones in yeast and humans. In the H. 
sapiens  Cu1+-CCS1 in which Cu1+ is bound at D1, forms a heterodimeric complex with E,Zn-SOD1 (A). D1 of CCS1 transfers Cu1+ to SOD1 and disulfide 
formation within the CXC motif occurs and D3 is orientated towards the SOD1 active site (B). Finally, disulphide isomerisation from D3 of CCS1 to 
SOD1 occurs (C and D). In S. cerevisiae, Cu1+ is possibly first recruited by the CXXC motif of Ccs1 D1 and transferred to the CXC motif of D3 (E). Cu1+-
Ccs1 forms a heterodimeric complex with Sod1 (F).  D3 of Ccs1 orientates towards the Sod1 active site (G). D3 of Ccs1 transfers Cu1+ to Sod1 and 
disulphide formation occurs within the CXC motif of D3 in Ccs1 (H).  Finally, disulfide isomerisation from D3 of CCS1 to SOD1 occurs (I and J). . The H. 
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